Document:

<PAGE>

                                                                   Exhibit 10.35

--------------------------------------------------------------------------------
Portions of this exhibit have been omitted pursuant to a request for
confidential treatment of those portions filed with the Securities and Exchange
Commission. Such confidential portions have been filed with the Securities and
Exchange Commission and are denoted in this exhibit by an asterisk (*).
--------------------------------------------------------------------------------

================================================================================

                            LIMITED LIABILITY COMPANY
                               OPERATING AGREEMENT
                                       of
                                  COLLORAL LLC

                      a Delaware Limited Liability Company

                           Dated as of August 19, 2002

================================================================================

<PAGE>

                                  COLLORAL LLC

                               OPERATING AGREEMENT

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            Page
                                                                            ----
<S>                                                                          <C>
1.  ORGANIZATION. ........................................................   1
    1.1  Formation .......................................................   1
    1.2  Name ............................................................   1
    1.3  Certificate of Formation; Filings ...............................   1
    1.4  Business Purpose ................................................   1
    1.5  Fictitious Business Name Statements .............................   1
    1.6  Principal Place of Business; Other Places of Business ...........   1
    1.7  Designated Agent for Service of Process .........................   2
    1.8  Term ............................................................   2
2.  POWERS ...............................................................   2
    2.1  Enter into Agreements ...........................................   2
    2.2  Borrowings ......................................................   2
    2.3  Expenses ........................................................   2
    2.4  Other Powers ....................................................   2
    2.5  Powers Not Otherwise Prohibited .................................   2
3.  MANAGEMENT ...........................................................   2
    3.1  Designation of Managers .........................................   2
    3.2  Managers as Members .............................................   3
    3.3  Management of the Company .......................................   3
    3.4  Board Action ....................................................   3
    3.5  Compensation of Managers and Members ............................   3
    3.6  Contracts with Affiliated Persons ...............................   3
    3.7  Other Activities ................................................   4
    3.8  Officers ........................................................   4
4.  MEMBERS AND CAPITAL CONTRIBUTIONS ....................................   4
    4.1  Capital Accounts ................................................   4
    4.2  Initial Members and Initial Capital Contributions ...............   4
    4.3  Additional Members ..............................................   4
    4.4  No Withdrawal of or Interest on Capital .........................   5
    4.5  Liability of Members ............................................   5
    4.6  Additional Capital Requirements .................................   5
    4.7  Third Party Liabilities .........................................   5
5.  DISTRIBUTIONS ........................................................   5
    5.1  Distribution of Company Funds ...................................   6
    5.2  Distribution of Member Recovery Amounts .........................   6
    5.3  Distribution Upon Dissolution ...................................   6
    5.4  Distribution of Assets in Kind ..................................   6
6.  ALLOCATION OF PROFITS AND LOSSES. ....................................   6
    6.1  Allocation of Profits and Losses ................................   7
</TABLE>

                                      -i-

<PAGE>

<TABLE>
<S>                                                                        <C>
7.  FISCAL MATTERS ......................................................   7
    7.1    Books and Records ............................................   7
    7.2    Bank Accounts ................................................   7
    7.3    Fiscal Year ..................................................   7
    7.4    Tax Matters Partner ..........................................   7
8.  TRANSFERS OF INTERESTS ..............................................   8
    8.1    General Restrictions on Transfer .............................   8
    8.2    Transfer by Operation of Law .................................   8
    8.3    Other Restrictions ...........................................   8
    8.4    Relief From Liability ........................................   9
    8.5    Party to Agreement ...........................................   9
    8.6    Contravention of Provisions ..................................   9
9.  DISSOLUTION AND TERMINATION .........................................   9
    9.1    Limitations ..................................................   9
    9.2    Events Causing Dissolution ...................................   9
    9.3    Procedures on Dissolution ....................................  10
    9.4    Special Dissolution Provisions ...............................  10
10. TAX ALLOCATION PROVISIONS ...........................................  10
    10.1   Required Regulatory Allocations ..............................  11
    10.2   Curative Allocations .........................................  12
    10.3   Tax Allocations and Book Allocations .........................  12
    10.4   General Allocation and Distribution Rules ....................  13
    10.5   Tax Withholding ..............................................  13
11. NON-COMPETITION .....................................................  14
12. REPRESENTATIONS AND WARRANTIES ......................................  14
    12.1   AI ...........................................................  14
    12.2   Deseret ......................................................  15
13. GENERAL PROVISIONS ..................................................  16
    13.1   Notices ......................................................  16
    13.2   Word Meanings ................................................  16
    13.3   Binding Provisions ...........................................  16
    13.4   Applicable Law ...............................................  16
    13.5   Counterparts .................................................  16
    13.6   Separability of Provisions ...................................  16
    13.7   Section Titles ...............................................  17
    13.8   Amendments ...................................................  17
    13.9   Entire Agreement .............................................  17
    13.10  Waiver of Partition ..........................................  17
    13.11  Public Announcements .........................................  17
    [13.12 Survival of Certain Provisions ...............................  17
14. DEFINITIONS .........................................................  17
</TABLE>

                                      -ii-

<PAGE>

COLLORAL LLC

OPERATING AGREEMENT

     This Operating Agreement, dated as of August 19, 2002, is by and between
AutoImmune Inc., and Deseret Laboratories, Inc.

1.   ORGANIZATION.

     1.1 Formation. COLLORAL LLC (the "Company") has been formed as a limited
liability company under the Delaware Limited Liability Company Act (the "Act")
for the purposes and upon the terms and conditions hereinafter set forth. The
rights and liabilities of the Members of the Company shall be as provided in the
Act, except as otherwise expressly provided herein. In the event of any
inconsistency between any terms and conditions contained in this Agreement and
any nonmandatory provisions of the Act, the terms and conditions contained in
this Agreement shall govern.

     1.2 Name. The name of the Company shall be COLLORAL LLC. The Company may
also conduct business at the same time under one or more fictitious names if the
Board of Managers of the Company (the "Board") determines that it is in the best
interests of the Company. The Board may change the name of the Company, from
time to time, in accordance with applicable law.

     1.3 Certificate of Formation; Filings. A Certificate of Formation (the
"Certificate") has been executed and filed in the Office of the Delaware
Secretary of State as required by the Act. The Board may execute and file any
duly authorized amendments to the Certificate from time to time in a form
prescribed by the Act. The Board shall also cause to be made, on behalf of the
Company, such additional filings and recordings as the Board shall deem
necessary or advisable.

     1.4 Business Purpose. The Company shall engage solely in the business of
developing, manufacturing, marketing and selling Licensed Products (as defined
in the License Agreement of even date herewith between AI and the Company) as
non-prescription products for the treatment of arthritic conditions and any
activities ancillary thereto.

     1.5 Fictitious Business Name Statements. Fictitious business name
statements will be filed and published when and if the Board determines such
statements are necessary. Any such statement shall be renewed as required by
applicable law.

     1.6 Principal Place of Business; Other Places of Business. The principal
place of business of the Company shall be at such place within or outside the
State of Delaware as the Board may from time to time designate. The Board may
direct that the Company maintain offices and places of business at such other
place or places within or outside the State of Delaware, as and when required by
the Company's business and in furtherance of the general character of the
Company's business described in the Certificate, and may appoint agents for
service of process in all jurisdictions in which the Company shall conduct
business. The Board shall file such certificates and documents as are necessary
under the laws of any jurisdictions in which the Company shall conduct business.

<PAGE>

     1.7 Designated Agent for Service of Process. The Company shall continuously
maintain a registered office and a designated and duly qualified agent for
service of process on the Company in the State of Delaware.

     1.8 Term. The Company shall commence on the date that the Certificate is
filed with the Office of the Delaware Secretary of State, and shall continue
until terminated pursuant to this Agreement.

2.   POWERS.   Subject to all other provisions of this Agreement, in furtherance
of the conduct of the business purpose described in Section 1.4, the Company is
authorized to take those actions listed in this Section 2.

     2.1 Enter into Agreements. The Company may enter into, execute, modify,
amend, supplement, acknowledge, deliver, perform, and carry out contracts of any
kind, including operating agreements of limited liability companies, whether as
a member or manager, contracts with Affiliated Persons, including guarantees and
joint venture, limited and general partnership agreements and contracts
establishing business arrangements or organizations, necessary to, in connection
with, or incidental to the accomplishment of the permitted business of the
Company, and to secure the same by mortgages, pledges or other liens.

     2.2 Borrowings. The Company may borrow money and issue evidences of
indebtedness in furtherance of the permitted business of the Company, and to
secure the same by mortgages, pledges, or other liens.

     2.3 Expenses. To the extent that funds of the Company are available, the
Company may pay all expenses, debts and obligations of the Company.

     2.4 Other Powers. The Company may exercise all the powers and privileges
granted by the Act or any other law or this Agreement, together with any powers
incidental thereto, so far as such powers are necessary or convenient to the
conduct, promotion, or attainment of the permitted business, trade, purposes, or
activities of the Company.

     2.5 Powers Not Otherwise Prohibited. The Company may take any other action
not prohibited under the Act or other applicable law and permitted under Section
1.4.

3.   MANAGEMENT.

     3.1 Designation of Managers. The number of Managers of the Company shall be
initially fixed at 3 and shall be the Persons named in Schedule I hereto.
Subject to the provisions set forth below, any Person may be elected as a
Manager at any time by the unanimous consent of the Members. Each Member agrees
to vote in favor of the following actions:

     (a) to cause and maintain the election to the Board of one Manager
designated by AI (the "AI Manager"); and

     (b) to cause and maintain the election to the Board of two Managers
designated by Deseret (the "Deseret Managers").

                                      -2-

<PAGE>

     Each Manager shall hold office until such individual is removed by the
Member which designated him or her, resigns or dies. In the event that any
Manager dies, resigns or is unable or unwilling to serve as such, or is removed
from office by the Member that designated him or her, the Members shall promptly
elect a successor consistent with the provisions of this Section 3.1.

     3.2 Managers as Members. Any Manager may, but need not, hold an Interest in
the Company as a Member, and such person's rights and interest as a Manager
shall be distinct and separate from such person's rights and Interest as a
Member.

     3.3 Management of the Company. Subject to the provisions of this Agreement
that require the consent of the Members, the Board shall have the exclusive
power and authority to manage the business and affairs of the Company and to
make all decisions with respect thereto. Except as otherwise expressly provided
in this Agreement, the Board or Persons designated by the Board, including
officers and agents appointed by the Board, shall be the only Persons authorized
to execute documents binding on the Company. To the fullest extent permitted by
Delaware law, but subject to any specific provisions in this Agreement granting
rights to the Members, the Board shall have the power to perform any acts,
statutory or otherwise, with respect to the Company or this Agreement, which
would otherwise be possessed by the Members under Delaware law, and the Members
shall have no power whatsoever with respect to the management of the business
and affairs of the Company.

     3.4 Board Action. Any action to be taken by the Board shall require the
approval of a majority of the Board; provided, that such majority consists of
the AI Manager and at least one Deseret Manager and; provided, further, that
with respect to any matter, agreement or claim involving the Company, on the one
hand, and a Member or an Affiliated Person of a Member, on the other hand, the
Board shall act solely with the approval of the AI Manager if such Member is
Deseret or if the matter, agreement or claim involves an Affiliated Person of
Deseret and solely with the approval of the Deseret Manager if such Member is AI
or if the matter, agreement or claim involves an Affiliated Person of AI.
Subject to the foregoing, the Board may take action by less than unanimous
written consent.

     3.5 Compensation of Managers and Members. No payment shall be made by the
Company to any Manager or Member for such Manager or Member's services as a
Manager or Member except as expressly provided in this Agreement. Each Manager
shall be entitled to reimbursement from the Company for all out-of pocket
expenses reasonably incurred by such Manager in managing and conducting the
business and affairs of the Company. The Board shall determine which expenses,
if any, are allocable to the Company in a manner which is fair and reasonable to
the Managers and the Company, and if such allocation is made in good faith it
shall be conclusive in the absence of manifest error. The foregoing shall not
prohibit payments and reimbursements to any Manager or Member who is also an
officer of the Company, in such Person's capacity as an officer, to the extent
approved by the Board.

     3.6 Contracts with Affiliated Persons. The Company may enter into one or
more oral or written agreements, leases, contracts or other arrangements for the
furnishing to or by the Company of goods, services or space with any Member,
Manager or Affiliated Person (including as an officer pursuant to Section 3.8 or
as a non-officer employee), and may pay compensation thereunder for such goods,
services or space.

                                      -3-

<PAGE>

     3.7 Other Activities. Except as set forth in Section 11, the Members,
Managers and any Affiliates of any of them may engage in and possess interests
in other business ventures and investment opportunities of every kind and
description, independently or with others, including serving as managers and
general partners of other limited liability companies and partnerships with
purposes similar to those of the Company. Neither the Company nor any other
Member or Manager shall have any rights in or to such ventures or opportunities
or the income or profits therefrom.

     3.8 Officers. The Board may from time to time designate one or more Persons
to be officers of the Company, each of whom shall serve at the pleasure of the
Board. The Board shall delegate to each such officer the authority and duties
that are set forth in the resolution appointing the officer and in any
subsequent resolution adopted by the Board, and such officer shall have full
authority to act within the scope of such delegated authority, including by
binding the Company to the extent provided therein. The Board may assign titles
to particular officers. Each such officer shall hold office until his successor
shall be duly designated and qualified, or until his death, or until he shall
resign or shall have been removed by resolution adopted by the Board. Any number
of offices may be held by the same Person. The salaries or other compensation,
if any, of the officers and agents of the Company shall be fixed from time to
time by the Board.

4.   MEMBERS AND CAPITAL CONTRIBUTIONS.

     4.1 Capital Accounts. A separate Capital Account shall be maintained for
each Member, including any Member who shall hereafter acquire an Interest in the
Company. Capital Accounts shall be maintained in accordance with the provisions
of ss. 704 of the Code and the Regulations thereunder, except as provided
herein.

     4.2 Initial Members and Initial Capital Contributions. On the date of this
Agreement, each of the Members has contributed to the capital of the Company the
amount of cash, or property having an agreed value, set forth opposite its name
on Schedule I. If so required by a vote of the Board (such vote to include the
vote of the AI Manager and at least one Deseret Manager), Deseret may be
required to make an additional capital contribution or contributions, in cash,
in an aggregate amount not to exceed * dollars ($* ) in the event that the
business of the Company (if so determined at the sole discretion of the Board)
requires additional capital. Such additional capital contributions shall be
refundable to Deseret if the Board, in its sole discretion, determines they are
no longer needed and so votes (such vote to include the vote of the AI Manager
and at least one Deseret Manager). Such as vote shall not be a conflict of
interest for Deseret.

     4.3 Additional Members. Additional Persons may be admitted to the Company
as Members, and additional Interests may be created, all on the terms and
conditions approved by the Board at the time of admission, subject to the
Company's receipt of such Capital Contribution (if any) as may be agreed upon
between the Board and such Person. Notwithstanding the foregoing, the terms of
admission or issuance may not create any class or series of Interests having
rights, powers or duties senior to those of any existing Interests unless the
Board has obtained the unanimous consent of the Members holding the Interests in
such junior class(es). The Board shall reflect the creation of additional
Interests by amendment of Schedule I hereto, and shall reflect the creation of
any new class or series in an amendment to this Agreement indicating the
different rights, powers and duties possessed by the several classes or series
of Interests, either of which amendments need be executed only by the Board.

                                      -4-

<PAGE>

     4.4 No Withdrawal of or Interest on Capital. No Member shall have the right
to resign and receive any distribution from the Company as a result of such
resignation, and no Member shall have the right to receive the return of all or
any part of its Capital Contributions or Capital Account, or any other
distribution, except as provided in Sections 5 and 9.3. No Member shall have any
right to demand and receive property of the Company in exchange for all or any
portion of its Capital Contributions or Capital Account, except as provided in
Sections 5 and 9.3 upon dissolution and liquidation of the Company. No interest
or prior or preferred return shall accrue or be paid on any Capital Contribution
or Capital Account except pursuant to Section 5 as the same may be hereafter
amended.

     4.5 Liability of Members. Except as set forth in this Section 4, no Member
shall be entitled, obligated or required to make any capital contribution in
addition to its Capital Contribution made under Section 4.2 or 4.3, or any loan
to the Company. No Member, in its capacity as a Member, shall have any liability
to restore any negative balance in its Capital Account or to contribute to, or
in respect of, the liabilities or the obligations of the Company, or to restore
any amounts distributed from the Company, except as may be required under the
Act or other applicable law. In no event shall any Member, in its capacity as a
Member, be personally liable for any liabilities or obligations of the Company.

     4.6 Additional Capital Requirements.

         (a) In addition to the additional capital contribution that may be
requested of Deseret pursuant to Section 4.2, in the event that the Company
requires additional funds to carry out its purposes, to conduct its business, or
to meet its obligations, the Company may create additional Interests as the
Board may determine, or may borrow funds from such lender(s) as the Board may
determine, in each case including any one or more Managers or existing Members,
all on such terms and conditions as are approved by the Board.

         (b) No loan made to the Company by any Member shall constitute a
Capital Contribution to the Company for any purpose.

         (c) No Member or Manager shall have any obligation to give notice of an
existing or potential default of any obligation of the Company to any of the
Members or Managers, nor shall any Member or Manager be obligated to make any
Capital Contributions or loans to the Company, or otherwise supply or make
available any funds to the Company, even if the failure to do so would result in
a default of any of the Company's obligations or the loss or termination of all
or any part of the Company's assets or business.

     4.7 Third Party Liabilities. The provisions of this Section 4 are not
intended to be for the benefit of any creditor or other Person (other than a
Member in its capacity as a Member) to whom any debts, liabilities, or
obligations are owed by (or who otherwise has any claim against) the Company or
any of the Members. Moreover, notwithstanding anything contained in this
Agreement, including specifically but without limitation this Section 4, no such
creditor or other Person shall obtain any rights under this Agreement or shall,
by reason of this Agreement, make any claim in respect of any debt, liability,
or obligation (or otherwise) against the Company or any Member.

5.   DISTRIBUTIONS

                                      -5-

<PAGE>

     5.1 Distribution of Company Funds. Except as provided in this Section 5,
all Company funds, which are determined by the Board to be available for
distribution shall be distributed to the Members on a quarterly basis as
follows:

         (a) First, to the Members in the following proportions: * percent (*%)
to AI and * percent (*%) to Deseret until an aggregate of $* is distributed
pursuant to this Section 5.1 in a fiscal year; and

         (b) Second, the balance for the fiscal year shall be allocated equally
between the Members.

         It is the intention of the Company to distribute each quarter all cash
and liquid assets of the Company other than such cash as the Board deems prudent
to maintain in the Company in connection with the operation of the Company's
business.

     5.2 Distribution of Member Recovery Amounts. Notwithstanding any other
provision in this Section 5, all Member Recovery Amounts received by the Company
shall be distributed to the Member which has not paid the Member Recovery Amount
to the Company as soon as is reasonably practicable.

     5.3 Distribution Upon Dissolution. Proceeds from a Terminating Capital
Transaction and amounts available upon dissolution, and after payment of, or
adequate provision for, the debts and obligations of the Company, and
liquidation of any remaining assets of the Company, shall be distributed and
applied in the following priority:

         (a) First, to fund reserves for liabilities not then due and owing and
for contingent liabilities to the extent deemed reasonable by the Board;
provided, that, upon the expiration of such period of time as the Board shall
deem advisable, the balance of such reserves remaining after payment of such
contingencies shall be distributed in the manner hereinafter set forth in this
Section 5.3; and

         (b) Second, to the Members, an amount sufficient to reduce the Members'
Capital Accounts to zero, in proportion to the positive balances in such Capital
Accounts (after reflecting in such Capital Accounts all adjustments thereto
necessitated by (A) all other Company transactions (including distributions and
allocations of Profits and Losses and items of income, gain, deduction, and
loss) and (B) such Terminating Capital Transaction).

     5.4 Distribution of Assets in Kind. Notwithstanding the foregoing
provisions of this Section 5, in the event of a dissolution other than in
connection with a Terminating Capital Transaction, all equipment contributed to
the Company by AI pursuant to Section 4 shall be returned to AI. Except for the
foregoing, no Member shall have the right to require any distribution of any
assets of the Company in kind. If any assets of the Company are distributed in
kind, such assets shall be distributed on the basis of their fair market value
as determined by the Board. Any Member entitled to any interest in such assets
shall, unless otherwise determined by the Board, receive separate assets of the
Company and not an interest as tenant-in-common, with other Members so entitled,
in each asset being distributed.

6.   ALLOCATION OF PROFITS AND LOSSES.

                                      -6-

<PAGE>

     6.1 Allocation of Profits and Losses.

         (a) After giving effect to the allocations set forth in Sections 10.1
and 10.2, and subject to the other provisions of Section 10 and of Section 6.2,
Profits for each fiscal year shall be allocated in the following order and
priority:

             (i)   First, in proportion to any deficit Capital Account balances,
until such deficits are eliminated; and

             (ii)  Second, of the next $* in Profits, after taking account of
the allocations to the Members pursuant to Section 6.1(a)(i) (if any), (A) *
percent (*%) shall be allocated to AI and (B) * percent (*%) shall be allocated
to Deseret; and

             (iii) Third, any remaining Profits shall be allocated equally
between the Members.

         (b) After giving effect to the allocations set forth in Section 10.1
and 10.2, and subject to the other provisions of Section 10, Losses for each
fiscal year shall be allocated in the following order and priority:

             (i)   First, to each Member to reduce the balance in its Capital
Account to zero; and

             (ii)  Second, any remaining Losses shall be allocated equally
between the Members.

     6.2 Special Allocations. All Member Recovery Amounts received by the
Company shall be allocated one hundred (100%) by the Company to the Member which
has not, or the Affiliate of which has not, paid the Member Recovery Amount to
the Company.

7.   FISCAL MATTERS.

     7.1 Books and Records. The Board shall keep or cause to be kept complete
and accurate books and records of the Company in accordance with generally
accepted accounting principles consistently applied. Such documents and
information as are required to be furnished to the Members under the Act shall
be made available at an office of the Company for examination and copying by any
Member or Manager, or his, her, or its duly authorized representative, at his
reasonable request and at his expense during ordinary business hours.

     7.2 Bank Accounts. Bank accounts and/or other accounts of the Company shall
be maintained in such banking and/or other financial institution(s) as shall be
selected by the Board, and withdrawals shall be made and other activity
conducted on such signature or signatures as shall be approved by the Board.

     7.3 Fiscal Year. The fiscal year of the Company shall end on December 31 of
each year.

     7.4 Tax Matters Partner. The Tax Matters Partner shall be the Person so
named in Schedule I hereto. At any time and from time to time if there is no Tax
Matters Partner, a Tax

                                      -7-

<PAGE>

Matters Partner may be designated by the Board. The Tax Matters Partner is
hereby authorized to, and shall perform all duties of, a "tax matters partner"
under the Code and shall serve as Tax Matters Partner until his, her, or its
resignation or until the designation of his, her, or its successor, whichever
occurs sooner.

8.   TRANSFERS OF INTERESTS.

     8.1 General Restrictions on Transfer. No Member may Transfer all or any
part of its Interest, or otherwise withdraw from the Company, except (i) with
the prior written approval of the Board, which may be withheld for any reason or
for no reason, (ii) in connection with Transfers to Affiliates, and (iii) in
connection with the sale of all or substantially all of the assets of the Member
or the business of the Member of which the activities of the Company are a part.
No transferee of a Transfer, including without limitation an Affiliate, may be
admitted as a Member except with the prior written approval of the Board, which
may be withheld for any reason or for no reason, and upon the satisfaction of
the other requirements of this Agreement.

     8.2 Transfer by Operation of Law. No Person who becomes the holder by
operation of law of all or any part of an Interest may be admitted as a Member
except with the prior written approval of the Board, which may be withheld for
any reason or for no reason, and upon satisfaction of the other requirements of
this Agreement.

     8.3 Other Restrictions. Every Transfer of an Interest permitted by this
Section 8 shall nevertheless be subject to the following:

         (a) No Transfer of any Interest may be made if such Transfer would
cause or result in a breach of any agreement binding upon the Company or of then
applicable rules and regulations of any governmental authority having
jurisdiction over such Transfer. The Board may require as a condition of any
Transfer that the transferor assume all costs incurred by the Company in
connection therewith and furnish an opinion of counsel, satisfactory to the
Company both as to counsel and opinion, that the proposed Transfer complies with
applicable law, including federal and state securities laws, and does not cause
the Company to be an investment company as such term is defined in the
Investment Company Act of 1940, as amended.

         (b) The Board shall require, as a condition to the admission to the
Company as a Member of any transferee who is not otherwise a Member, that such
transferee demonstrate to the reasonable satisfaction of the Board that it is a
financially responsible Person or has one or more financially responsible
Persons who have affirmatively assumed the financial obligations of the
transferee under this Agreement, if any, on its behalf.

         (c) Notwithstanding anything contained herein to the contrary, no
Interest shall be transferred if, by reason of such Transfer, the classification
of the Company as an Company for federal income tax purposes would be adversely
affected or jeopardized, or if such Transfer would have any other substantial
adverse effect for federal income tax purposes.

         (d) In the event of any Transfer, there shall be filed with the Company
a duly executed and acknowledged counterpart of the instrument effecting such
Transfer. The transferee shall execute such additional instruments as shall be
reasonably required by the Board. If and for so long as such instruments are not
so executed and filed, the Company need not recognize any

                                      -8-

<PAGE>

such Transfer for any purpose, and the transferee shall be entitled only to the
rights which are required under the Act to be afforded to a transferee who does
not become a Member.

         (e) Upon the admission or withdrawal of a Member, this Agreement
(including without limitation Schedule I hereto) and/or the Certificate shall be
amended appropriately by the Board to reflect the then existing names and
addresses of the Members.

     8.4 Relief From Liability. A transferor of an Interest shall, if the
transferee is a Member hereunder or if the transferee becomes a Member pursuant
to the provisions of this Agreement, be relieved of liability under this
Agreement with respect to the transferred Interest arising or accruing on or
after the effective date of the Transfer.

     8.5 Party to Agreement. Any Person who acquires in any manner whatsoever an
Interest (or any part thereof), whether or not such Person has accepted and
assumed in writing the terms and provisions of this Agreement or been admitted
into the Company as a Member as provided in this Section 8, shall be deemed, by
acceptance of the acquisition thereof, to have agreed to be subject to and bound
by all of the obligations of this Agreement with respect to such Interest and
shall be subject to the provisions of this Agreement with respect to any
subsequent Transfer of such Interest.

     8.6 Contravention of Provisions. Any Transfer in contravention of any of
the provisions of this Agreement shall be null and void and ineffective to
transfer any Interest, and shall not bind, or be recognized by, or be recorded
on the books of, the Company, and any transferee or assignee in such transaction
shall not be or be treated as or deemed to be a Member for any purpose. In the
event any Member shall at any time Transfer an Interest in contravention of any
of the provisions of this Agreement, then each other Member shall, in addition
to all rights and remedies at law and equity, be entitled to a decree or order
restraining and enjoining such transaction, and the offending Member shall not
plead in defense thereto that there would be an adequate remedy at law, it being
expressly hereby acknowledged and agreed that damages at law would be an
inadequate remedy for a breach or threatened breach of the violation of the
provisions concerning such transactions set forth in this Agreement.

9.   DISSOLUTION AND TERMINATION.

     9.1 Limitations. The Company may be dissolved, liquidated, and terminated
only pursuant to the provisions of this Section 9, and the parties hereto do
hereby irrevocably waive any and all other rights they may have to a dissolution
of the Company or a sale or partition of any or all of the Company assets.

     9.2 Events Causing Dissolution. Notwithstanding the Act, the Company shall
be dissolved and its affairs wound up only upon the occurrence of any of the
following events:

         (a) A Terminating Capital Transaction; provided, that no Terminating
Capital Transaction may occur without the prior written approval of the Board
and the unanimous consent of the Members;

                                      -9-

<PAGE>

         (b) The election to dissolve the Company made in writing by the Board
with the unanimous consent of the Members;

         (c) Any consolidation or merger of the Company with or into any entity
in which the Company is not the resulting or surviving entity; provided, that no
such consolidation or merger may occur without the prior written approval of the
Board and the unanimous consent of the Members;

         (d) By either Member if the Board is deadlocked with respect to any
material matter brought before it for action and such deadlock has continued for
at least thirty days;

         (e) By the non-breaching Member in the event of any material breach of
the representations and warranties set forth in Section 12;

         (f) By either Member in the event of any material breach of this
Agreement by the other Member, which breach is not cured within fifteen days
after notice specifying the nature of such breach;

         (g) By either Member in the event of any breach by the other Member or
its Affiliates of the Manufacturing, Sales and Marketing Agreement, which breach
is not cured within ninety days after notice specifying the nature of such
breach, or in the event the Manufacturing, Sales and Marketing Agreement expires
or is terminated by Deseret in accordance with its terms;

         (h) By Deseret in the event of any breach by AI or its Affiliates of
the License Agreement or the Trademark Agreement, which breach is not cured
within ninety days after notice specifying the nature of such breach; or

         (i) By either Member if a Change of Control has occurred with respect
to a Member.

     9.3 Procedures on Dissolution. Upon dissolution of the Company, the Board,
or if none, a liquidator elected by the unanimous consent of the Members, shall
liquidate the assets of the Company, apply and distribute the proceeds thereof
in accordance with Section 5 of this Agreement, and cause the cancellation of
the Certificate. The Company shall not terminate until the Certificate shall be
canceled.

     9.4 Special Dissolution Provisions. In the event of the dissolution of the
Company:

         (a) The provisions of Section 11 and the right to receive any Member
Recovery Amount shall inure to the Members and may be enforced by AI with
respect to Deseret and by Deseret with respect to AI; and

         (b) If dissolution occurs pursuant to Section 9.2(e), Section 9.2(f) or
Section 9.2(g) or Section 9.2(h), the non-breaching party shall be entitled to
any and all rights and remedies available to it at law or in equity with respect
to any and all breaches giving rise to such dissolution

10.  TAX ALLOCATION PROVISIONS.

                                      -10-

<PAGE>

     10.1 Required Regulatory Allocations.

          (a) Limitation on and Reallocation of Losses. At no time shall any
allocations of Losses, or any item of loss or deduction, be made to a Member if
and to the extent such allocation would cause such Member to have, or would
increase, any Adjusted Capital Account Deficit of such Member at the end of any
fiscal year. To the extent any Losses or items are not allocated to one or more
Members pursuant to the preceding sentence, such Losses shall be allocated to
the Members to which such losses or items may be allocated without violation of
this Section 10.1(a).

          (b) Minimum Gain Chargeback. If there is a net decrease in the Minimum
Gain of the Company during any fiscal year, then items of income or gain of the
Company for such fiscal year (and, if necessary, subsequent fiscal years) shall
be allocated to each Member in an amount equal to such Member's share of the net
decrease in the Minimum Gain, determined in accordance with Regulations (S)
1.704-2(d)(1). A Member's share of the net decrease in the Minimum Gain of the
Company shall be determined in accordance with Regulations (S) 1.704-2(g). The
items of income and gain to be so allocated shall be determined in accordance
with Regulations (S)(S) 1.704-2(f)(6) and 1.704-2(j)(2).

          (c) Partner Minimum Gain Chargeback. Notwithstanding any contrary
provisions of this Section 10, other than Section 10.1(b) above, if there is a
net decrease in Partner Minimum Gain attributable to Partner Nonrecourse Debt
during any fiscal year, then each Member who has a share of such Partner Minimum
Gain, determined in accordance with Regulations (S) 1.704-2(i), shall be
allocated items of income and gain of the Company, determined in accordance with
Regulations (S) 1.704-2(j)(2)(ii), for such fiscal year (and, if necessary,
subsequent fiscal years) in an amount equal to each such Member's share of the
net decrease in such Partner Minimum Gain, determined in accordance with
Regulations (S) 1.704-(2)(i).

          (d) Qualified Income Offset. If any Member unexpectedly receives an
item described in Regulations (S) 1.704-1(b)(2)(ii)(d)(4), (5), or (6), items of
income and gain shall be allocated to each such Member in an amount and manner
sufficient to eliminate, as quickly as possible and to the extent required by
Regulations (S) 1.704-1(b)(2)(ii)(d), the Adjusted Capital Account Deficit of
such Member; provided, that an allocation pursuant to this Section 10.1(d) shall
be made if and only to the extent that such Member would have an Adjusted
Capital Account Deficit after all other allocations provided for in this Section
10 have been tentatively made as if this Section 10.1(d) were not in the
Agreement.

          (e) Gross Income Allocation. In the event any Member has a Capital
Account deficit at the end of any Company fiscal year which is in excess of the
sum of the items to be credited to a Member's Capital Account under clause (a)
of the definition of Adjusted Capital Account Deficit, then each such Member
shall be allocated items of income and gain in the amount of such excess as
quickly as possible; provided, that an allocation pursuant to this Section
10.1(e) shall be made if, and only to the extent that, such Member would have a
Capital Account deficit in excess of such sum after all other allocations
provided for in this Section 10 have been tentatively made as if this Section
10.1(e) were not in this Agreement. As among Members having such excess, if
there are not sufficient items of income and gain to eliminate all such
excesses, such allocations shall be made in proportion to the amount of any such
excess.

                                      -11-

<PAGE>

          (f) Nonrecourse Deductions. Nonrecourse Deductions for any fiscal year
or other period (not including any Partner Nonrecourse Deductions allocated
pursuant to Section 10.1(g)) shall be allocated among the Members equally.
Solely for purposes of determining each Member's proportionate share of the
"excess nonrecourse liabilities" of the Company, within the meaning of
Regulations (S) 1.752-3(a)(3), each Member's interest in Company profits shall
be equal. The items of losses, deductions, and Code (S) 705(a)(2)(b)
expenditures to be so allocated shall be determined in accordance with
Regulations (S) 1.704-2(j)(1)(ii).

          (g) Partner Nonrecourse Deductions. Any Partner Nonrecourse Deductions
for any fiscal year or other period shall be allocated to the Member who bears
the economic risk of loss with respect to the nonrecourse liability (as
determined and defined under Regulations (S) 1.704-2(b)(4)) to which such
Partner Nonrecourse Deductions are attributable, in accordance with Regulations
(S) 1.704-2(i)(1). The items of losses, deductions, and Code (S) 705(a)(2)(b)
expenditures to be so allocated shall be determined in accordance with
Regulations (S) 1.704-2(j)(1)(ii).

          (h) Basis Adjustment. To the extent an adjustment to the adjusted tax
basis of any Company asset pursuant to either of Code (S)(S) 734(b) or 743(b) is
required pursuant to Regulations (S) 1.704-1(b)(2)(iv)(m) to be taken into
account in determining Capital Accounts, the amount of such adjustment to the
Capital Accounts shall be treated as an item of gain (if the adjustment
increases the basis of the asset) or loss (if the adjustment decreases such
basis) and such gain or loss shall be allocated to the Members in a manner
consistent with the manner in which their Capital Accounts are required to be
adjusted pursuant to such Section of the Regulations.

     10.2 Curative Allocations. The allocations set forth in Section 10.1 are
intended to comply with certain requirements of Regulations (S)(S) 1.704-1(b)
and 1.704-2 and shall be interpreted consistently therewith. Such allocations
may not be consistent with the manner in which the Members intend to divide
Company distributions and to make Profit and Loss allocations. Accordingly, by
the approval of the Board, other allocations of Profits, Losses, and items
thereof shall be made among the Members so as to prevent the allocations in
Section 10.1 from distorting the manner in which Company distributions will be
made among the Members pursuant to Sections 6.1 and 6.2 hereof. In general, the
Members anticipate that this will be accomplished by specially allocating other
Profits, Losses, and items of income, gain, loss, and deduction among the
Members so that the net amount of allocations under Section 10.1, and
allocations under this Section 10.2, to each such Member is zero. However, the
Board shall have discretion to accomplish this result in any reasonable manner.

     10.3 Tax Allocations and Book Allocations. Except as otherwise provided in
this Section 10.3, for federal income tax purposes, each item of income, gain,
loss, and deduction shall, to the extent appropriate, be allocated among the
Members in the same manner as its correlative item of "book" income, gain, loss,
or deduction has been allocated pursuant to the other provisions of this
Agreement.

     In accordance with Code (S) 704(c) and the Regulations thereunder,
depreciation, amortization, gain, and loss, as determined for tax purposes, with
respect to any property whose Book Value differs from its adjusted basis for
federal income tax purposes shall, for tax purposes, be allocated among the
Members so as to take account of any variation between the

                                      -12-

<PAGE>

adjusted basis of such property to the Company for federal income tax purposes
and its Book Value, such allocation to be made by the Board in any manner which
is permissible under said Code (S) 704(c) and the Regulations thereunder, and
the Regulations under Code (S) 704(b).

     In the event the Book Value of any property of the Company is subsequently
adjusted, subsequent allocations of income, gain, loss, and deduction with
respect to any such property shall take into account any variation between the
adjusted basis of such property for federal income tax purposes and its Book
Value in the manner provided under Code (S) 704(c) and the Regulations
thereunder.

     Allocations pursuant to this Section 10.3 are solely for purposes of
federal, state, and local taxes and shall not affect, or in any way be taken
into account in computing, any Member's Capital Account or share of Profits,
Losses, other items, or distributions pursuant to any provision of this
Agreement.

     10.4 General Allocation and Distribution Rules.

          (a) For purposes of determining the Profits, Losses, or any other
items allocable to any period, Profits, Losses, and any such other items shall
be determined on a daily, monthly, or other basis, as determined by the Board
using any permissible method under Code (S) 706 and the Regulations thereunder.
Except as otherwise provided in this Agreement, all items of income, gain, loss,
and deduction shall be allocable among the Members in the same proportions as
the Profits or Losses are allocated for the fiscal year in which such item is
included.

          (b) Upon the admission of a new Member or the Transfer of an Interest,
the new and old Members or the transferor and transferee shall be allocated
shares of Profits and Losses and other allocations and shall receive
distributions, if any, based on the portion of the fiscal year that the new or
transferred Interest was held by the new and old Members, or the transferor and
transferee, respectively. For the purpose of allocating Profits and Losses and
other allocations and distributions, (i) such admission or Transfer shall be
deemed to have occurred on the first day of the month in which it occurs, or if
such date shall not be permitted for allocation purposes under the Code or the
Regulations, on the nearest date otherwise permitted under the Code or the
Regulations, and (ii) if required by the Code or the Regulations, the Company
shall close its books on an interim basis on the last day of the previous
calendar month.

     10.5 Tax Withholding. If the Company incurs a withholding tax obligation
with respect to the share of income allocated to any Member, (a) any amount
which is (i) actually withheld from a distribution that would otherwise have
been made to such Member and (ii) paid over in satisfaction of such withholding
tax obligation shall be treated for all purposes under this Agreement as if such
amount had been distributed to such Member, and (b) any amount which is so paid
over by the Company, but which exceeds the amount, if any, actually withheld
from a distribution which would otherwise have been made to such Member, shall
be treated as an interest-free advance to such Member. Amounts treated as
advanced to any Member pursuant to this Section 10.5 shall be repaid by such
Member to the Company within 30 days after the Board gives notice to such Member
making demand therefor. Any amounts so advanced and not timely repaid shall bear
interest, commencing on the expiration of said 30 day period, compounded monthly
on unpaid balances, at an annual rate equal to the Applicable Federal Rate as of
such

                                      -13-

<PAGE>

expiration date. The Company shall collect any unpaid amounts from any Company
distributions that would otherwise be made to such Member.

11.  NON-COMPETITION.

     While a Member holds an Interest in the Company and, except for the
non-breaching Member if the Company is dissolved pursuant to Sections 9.2(e),
9.2(f), 9.2(g) or 9.2(h), for one year thereafter, such Member and its
Affiliates shall not engage or become interested, directly or indirectly, in the
operation, management or supervision of any type of business or enterprise that
at any time during such period manufactures, markets or sells a non-prescription
product containing Type II collagen for the treatment of arthritic conditions;
provided, however, that nothing contained in this Section 11 shall be deemed to
prohibit any Member or its Affiliates from performing contract manufacturing
activities for unrelated parties not involving a non-prescription product
containing Type II collagen for the treatment of arthritic conditions.
Notwithstanding the foregoing to the contrary, a Member may otherwise own shares
in a publicly-traded corporation or publicly-traded mutual fund or
publicly-traded limited partnership in which such Member's aggregate ownership
interest is one percent (1%) or le(S) The geographic scope of the limitations
set forth in this Section 11 is worldwide. Notwithstanding the foregoing, the
provisions of this Section 11 shall not apply (a) to the non-breaching Member if
the Company is dissolved pursuant to Sections 9.1(e), (f), (g) or (h) and to
that Member's Affiliates and (b) to AI if Deseret terminates the Manufacturing,
Sales and Marketing Agreement pursuant to Section 9.2.3 thereof. In the event
the Company is dissolved, the rights and obligations set forth in this Section
11 shall be assigned to the Members.

     If any restriction set forth in this Section 11 is found by a court of
competent jurisdiction to be unenforceable because it extends for too long a
period of time or over too great a range of activities or is too broad a
geographic area, it shall be interpreted to extend only over the maximum period
of time, range of activities or geographic area for which it may be enforceable.

     Each Member acknowledges that any breach of this Section 11 will result in
irreparable harm to the Company for which an adequate remedy at law does not
exist. Accordingly, each Member agrees that the Company, in addition to any
other available rights and remedies it may have, shall be entitled to receive
injunctive or other equitable relief, without the necessity of posting a bond,
for any breach of this Section 11.

12.  REPRESENTATIONS AND WARRANTIES.

     12.1 AI. AI hereby represents and warrants to Deseret and the Company as
follows:

          (a) AI is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware, with full corporate power and
authority to own, lease and operate its properties and to carry on the business
conducted by it and the transactions contemplated hereby.

          (b) The execution and delivery by AI of this Agreement and of the
agreements to be executed and delivered by it pursuant hereto, and the
performance by it of its obligations hereunder and thereunder, have been duly
and validly authorized by all necessary corporate action on the part of AI, and
AI has all necessary corporate power with respect thereto. This

                                      -14-

<PAGE>

Agreement and all of the aforementioned agreements are the valid and binding
obligations of AI enforceable against it in accordance with their respective
terms. Neither the execution and delivery by AI of this Agreement or any of the
aforementioned agreements, nor the consummation of the transactions contemplated
hereby or thereby, nor the performance by it of its obligations hereunder or
thereunder, will (nor with the giving of notice or the lapse of time or both
would) (i) conflict with or result in a breach of any provision of the charter
or by-laws of AI, or (ii) conflict with, give rise to a default, or any right of
termination, cancellation or acceleration, or otherwise result in a loss of
contractual benefits to AI under any of the terms, conditions or provisions of,
any note, bond, mortgage indenture, license, agreement or other instrument or
obligation to which AI is bound, or (iii) violate any order, writ, injunction,
decree, law, statute, rule or regulation applicable to AI, or (iv) result in the
creation or imposition of any lien, claim, restriction, charge or encumbrance
upon any of AI's assets or (v) interfere with or otherwise adversely affect the
ability of AI to carry on the activities contemplated by this Agreement.

          (c) Neither Deseret nor the Company shall have any liability for any
financial advisory fee, brokerage commission, finder's fee, or other like
payment in connection with any of the transactions contemplated hereby by reason
of actions taken by AI.

          (d) AI has obtained and there remains in effect all third party,
governmental and administrative consents, permits, appointments, approvals,
licenses, certificates and franchises necessary for the performance by AI of its
proposed activities contemplated under this Agreement.

     12.2 Deseret. Deseret hereby represents and warrants to AI and the Company
as follows:

          (a) Deseret is a corporation duly organized, validly existing and in
good standing under the laws of Utah, with full corporate power and authority to
own, lease and operate its properties and to carry on the business conducted by
it and the transactions contemplated hereby.

          (b) The execution and delivery by Deseret of this Agreement and the
agreements to be executed and delivered by it pursuant hereto, and the
performance by it of its obligations hereunder and thereunder, have been duly
and validly authorized by all necessary corporate action on the part of Deseret,
and Deseret has all necessary corporate power with respect thereto. This
Agreement and all of the aforementioned agreements are the valid and binding
obligations of Deseret enforceable against it in accordance with their
respective terms. Neither the execution and delivery by Deseret of this
Agreement or any of the aforementioned agreements, nor the consummation of the
transactions contemplated hereby or thereby, nor the performance by it of its
obligations hereunder or thereunder, will (nor with the giving of notice or the
lapse of time or both would) (i) conflict with or result in a breach of any
provision of the charter or by-laws of Deseret, or (ii) conflict with, give rise
to a default, or any right of termination, cancellation or acceleration, or
otherwise result in a loss of contractual benefits to Deseret under any of the
terms, conditions or provisions of, any note, bond, mortgage, indenture,
license, agreement or other instrument or obligation to which Deseret is bound,
or (iii) violate any order, writ, injunction, decree, law, statute, rule or
regulation applicable to Deseret, or (iv) result in the creation or imposition
of any lien, claim, restriction, charge or encumbrance upon

                                      -15-

<PAGE>

any of Deseret's assets or (v) interfere with or otherwise adversely affect the
ability of Deseret to carry on the activities contemplated by this Agreement.

          (c) Neither AI nor the Company shall have any liability for any
financial advisory fee, brokerage commission, finder's fee, or other like
payment in connection with any of the transactions contemplated hereby by reason
of actions taken by Deseret.

          (d) Deseret has obtained and there remain in effect all third party
governmental and administrative consents, permits, appointments, approvals,
licenses, certificates and franchises necessary for the performance by Deseret
of its proposed activities contemplated under this Agreement.

13.  GENERAL PROVISIONS.

     13.1 Notices. Any and all notices under this Agreement shall be effective
(a) upon delivery, if delivered in hand, (b) on the third business day after
being sent by registered or certified mail, return receipt requested, postage
prepaid, or (c) on the first business day after being sent by commercial
overnight delivery service providing a receipt for delivery. All such notices in
order to be effective shall be in writing and addressed, if to the Company, at
its registered office under the Act and, if to a Member, at the last address of
record on the Company books. Copies of such notices shall also be sent to the
last address for the recipient which is known to the sender, if different from
the address so specified.

     13.2 Word Meanings. Words such as "herein," "hereinafter," "hereof," and
"hereunder" refer to this Agreement as a whole and not merely to a subdivision
in which such words appear unless the context otherwise requires. The singular
shall include the plural, and the masculine gender shall include the feminine
and neuter, and vice versa, unless the context otherwise requires.

     13.3 Binding Provisions. Subject to the restrictions on transfer set forth
herein, the covenants and agreements contained herein shall be binding upon, and
inure to the benefit of, the parties hereto, their heirs, Legal Representatives,
and permitted successors and assigns, and any other Person who is issued or who
is otherwise acquires any Interest at any time.

     13.4 Applicable Law. This Agreement, including its existence, validity,
construction, and operating effect, and the rights of each of the parties
hereto, shall be governed by and construed in accordance with the laws of the
State of Delaware without regard to otherwise governing principles of conflicts
of law.

     13.5 Counterparts. This Agreement may be executed in several counterparts
and, as so executed, shall constitute one agreement binding on all parties
hereto, notwithstanding that all of the parties have not signed the original or
the same counterpart.

     13.6 Separability of Provisions. Each provision of this Agreement shall be
considered separable. If, for any reason, any provision or provisions herein are
determined to be invalid and contrary to any existing or future law, such
invalidity shall not impair the operation of or affect those portions of this
Agreement which are valid, and if for any reason any provision or

                                      -16-

<PAGE>

provisions herein would cause the Members to be liable for or bound by the
obligations of the Company, such provision or provisions shall be deemed void
and of no effect.

         13.7  Section Titles. Section titles are for descriptive purposes only
and shall not control or alter the meaning of this Agreement as set forth in the
text.

         13.8  Amendments. Except as otherwise specifically provided herein,
including without limitation in Section 8.3(e), this Agreement may be amended or
modified only with the approval of the Board and the unanimous consent of the
Members. No Member shall have any preemptive, preferential, or other right with
respect to the issuance or sale of any Interests, or any warrants,
subscriptions, options or other rights with respect thereto.

         13.9  Entire Agreement. This Agreement embodies the entire agreement
and understanding between the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and understandings relating to such
subject matter.

         13.10 Waiver of Partition. Each Member agrees that irreparable damage
would be done to the Company if any Member brought an action in court to
dissolve the Company except in accordance with this Agreement. Accordingly,
unless otherwise expressly authorized in this Agreement, each Member agrees that
it shall not, either directly or indirectly, take any action to require
partition or appraisement of the Company or of any of the assets or properties
of the Company and, notwithstanding any provisions of this Agreement to the
contrary, each Member (and its successors and assigns) accepts the provisions of
the Agreement as its sole entitlement on termination, dissolution, and/or
liquidation of the Company and hereby irrevocably waives any and all right to
maintain any action for partition or to compel any sale or other liquidation
with respect to its interest, in or with respect to, any assets or properties of
the Company; and each Member agrees that it will not petition a court for the
dissolution, termination or liquidation of the Company except to the extent
permitted by this Agreement.

         13.11 Public Announcements. The Members agree that press releases and
other announcements to be made by either of them in relation to this Agreement
shall be subject to the written consent of the other party, which consent shall
not be unreasonably withheld or delayed, except to the extent otherwise required
by law. The parties will agree to issue a joint press release immediately
following the execution of this Agreement, the form and content of which shall
be reasonably satisfactory to parties.

         13.12 Survival of Certain Provisions. The following Sections shall
survive the dissolution and termination of the Company: 4.5, 9.4, 11, 12 and
13.12.

14.      DEFINITIONS the following defined terms used in this Agreement shall
have the meanings specified below:

         "Act" means the Delaware Limited Liability Company Act, in effect at
the time of the initial filing of the Certificate with the office of the
Secretary of the State of Delaware, and as thereafter amended from time to time.

                                      -17-

<PAGE>

         "Adjusted Capital Account Deficit" means, with respect to any Member,
the deficit balance, if any, in such Member's Capital Account as of the end of
the relevant fiscal year, after giving effect to the following adjustments:

         (a) credit to such Capital Account any amounts which such Member is
obligated to restore pursuant to any provision of this Agreement or is deemed to
be obligated to restore pursuant to Regulations (S)(S) 1.704-2(g)(1) and
1.704-2(i)(5); and

         (b) debit to such Capital Account the items described in Regulations
(S) 1.704-1(b)(2)(ii)(d)(4), (5) and (6).

         The foregoing definition is intended to comply with the provisions of
Regulations (S) 1.704-1(b)(2)(ii)(d) and shall be interpreted consistently
therewith.

         "Affiliated Person" or "Affiliate" means, with reference to a specified
Person any entity or person that directly or indirectly controls, is controlled
by or is under common control with such Person. For purposes of this definition,
"control" shall mean the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of an entity,
whether through the ownership of voting securities, by contract or otherwise.

         "Agreement" means this Operating Agreement as it may be amended,
supplemented, or restated from time to time.

         "AI" means Autoimmune Inc., a Member.

         "AI Manager" shall have the meaning given in Section 3.1.

         "Applicable Federal Rate" means the Applicable Federal Rate as that
term is defined in Code (S) 7872, whether the short-term, mid-term or long-term
rate, as the case may be, as published from time to time by the Secretary of the
Treasury.

         "Board" means the Board of Managers of the Company.

         "Book Value" means, with respect to any asset of the Company, such
asset's adjusted basis for federal income tax purposes, except that:

             (i)  the initial Book Value of any asset contributed by a Member to
the Company shall be the gross fair market value of such asset (not reduced for
any liabilities to which it is subject or which the Company assumes), as such
value is determined and for which credit is given to the contributing Member
under this Agreement;

             (ii) the Book Values of all assets of the Company shall be adjusted
to equal their respective gross fair market values, as determined by the Board,
at and as of the following times:

         (a) the acquisition of an additional or new Interest by a new or
existing Member in exchange for other than a de minimis capital contribution, or
in exchange for services by such Member, if the Board reasonably determines that
such adjustment is necessary or appropriate to reflect the relative economic
interests of the Members;

                                      -18-

<PAGE>

         (b) the distribution by the Company to a Member of more than a de
minimis amount of any asset of the Company (including cash or cash equivalents)
as consideration for all or any portion of the Member's Interest, if the Board
reasonably determines that such adjustment is necessary or appropriate to
reflect the relative economic interests of the Members;

         (c) the liquidation of the Company within the meaning of Regulations
(S) 1.704-1(b)(2)(ii)(g); and

             (iii) the Book Value of the assets of the Company shall be
increased (or decreased) to reflect any adjustment to the adjusted basis of such
assets pursuant to Code (S) 734(b) or Code (S) 743(b), but only to the extent
such adjustments are taken into account in determining Capital Accounts pursuant
to Regulations (S) 1.704-1(b)(2)(iv)(m); provided, however, that Book Value
shall not be adjusted pursuant to this clause (iii) to the extent that the Board
determines that an adjustment pursuant to clause (ii) hereof is necessary or
appropriate in connection with the transaction that would otherwise result in an
adjustment pursuant to this clause (iii).

         If the Book Value of an asset has been determined or adjusted pursuant
to the preceding clauses (i), (ii), or (iii), such Book Value shall thereafter
be adjusted by the Depreciation taken into account with respect to such asset
for purposes of computing Profits and Losses, and the amount of the adjustment
shall thereafter be taken into account as gain or loss from the distribution of
such asset for purposes of computing Profits or Losses.

         "Capital Account" of any Member shall mean the Capital Account of such
Member referred to in Section 4.1 hereof.

         "Capital Contribution" means the amount of cash and the value of any
other property contributed to the Company by a Member with respect to such
Member's Interest, net of liabilities relating to such contributed property that
the Company assumes or to which the Company takes subject under Code (S) 752.
Any non-cash property shall be valued by agreement of the Board and the
contributing Member, which valuation shall be conclusive.

         "Certificate" means the Certificate of Organization creating the
Company, as it may from time to time be amended in accordance with the Act.

         "Change of Control" shall be deemed to have taken place if (i) any
"person" (as such term is used in Sections 13(d) and 14(d)(2) of the Securities
Exchange Act of 1934, as amended) is or becomes the beneficial owner, directly
or indirectly, of securities of a Member representing 50% or more of the
combined voting power of the Member's then outstanding securities or (ii) a
Member is a party to a reorganization, merger or consolidation with respect to
which persons who were shareholders of the Member immediately prior to such
reorganization, merger or consolidation do not, immediately thereafter, own more
than 50% of the combined voting power entitled to vote generally in the election
of directors of the reorganized, merged or consolidated company's then
outstanding voting securities, or (iii) a Member liquidates or dissolves or (iv)
a Member sells all or substantially all of its assets.

         "Code" means the Internal Revenue Code of 1986, as amended from time to
time, and any subsequent federal law of similar import.

                                      -19-

<PAGE>

         "Company" means the limited liability company formed pursuant to the
Certificate and this Agreement, as it may from time to time be constituted and
amended.

         "Depreciation" means, for each year or other period, an amount equal to
the depreciation, amortization or other cost recovery deduction allowable for
federal income tax purposes with respect to an asset for such year or other
period, except that if the Book Value of an asset differs from its adjusted
basis for federal income tax purposes at the beginning of such year or other
period, Depreciation shall be an amount that bears the same relationship to the
Book Value of such asset as the depreciation, amortization, or other cost
recovery deduction computed for tax purposes with respect to such asset for such
period bears to the adjusted tax basis for such asset or, if such asset has a
zero adjusted tax basis, Depreciation shall be determined with reference to the
initial Book Value of such asset using any reasonable method selected by the
Board, but not less than depreciation allowable for tax purposes for such year.

         "Deseret" means Deseret Laboratories, Inc., a Member.

         "Deseret Manager" shall have the meaning given in Section 3.1.

         "Interest" means the entire equity interest (or "limited liability
company interest" as such term is used in the Act) of a Member in the Company
and all rights and liabilities associated therewith, including without
limitation rights to distributions (liquidating or otherwise), allocations,
information, and rights to consent or approve.

         "Legal Representative" means, with respect to any individual, a duly
appointed executor, administrator, guardian, conservator, personal
representative, or other legal representative appointed as a result of the death
or incompetency of such individual.

         "License Agreement" means the License Agreement between AI and the
Company of even date herewith.

         "Losses" shall have the meaning provided below under the heading
"Profits and Losses."

         "Managers" shall refer to the Person(s) named as Managers in this
Agreement and any Person who becomes an additional, substitute, or replacement
Manager as permitted by this Agreement, in each such Person's capacity as a
Manager of the Company.

         "Manufacturing, Sales and Marketing Agreement" means the Manufacturing,
Sales and Marketing Agreement among the Company, AI and Deseret of even date
herewith.

         "Member" shall refer to any Person named as a Member in this Agreement
and any Person who becomes an additional, substitute, or replacement Member as
permitted by this Agreement, in each such Person's capacity as a Member of the
Company; and "Members" shall refer to all such Persons collectively.

         "Minimum Gain" shall have the meaning given in Regulations (S)
1.704-2(d).

         "Member Recovery Amount" shall be any amount paid to the Company by a
Member or an Affiliate of such Member (a) as damages or otherwise with respect
to the breach by such Member or its Affiliate of any obligation owed to the
Company or in connection with any

                                      -20-

<PAGE>

agreement by such Member or its Affiliate with the Company and (b) pursuant to
any indemnification obligations of such Member or its Affiliate to the Company.

         "Nonrecourse Deductions" shall have the meaning given in Regulations
(S) 1.704-2(b)(1).

         "Partner Minimum Gain" shall mean an amount, with respect to each
Partner Nonrecourse Debt, equal to the Partnership Minimum Gain that would
result if such Partner Nonrecourse Debt were treated as a nonrecourse liability,
determined in accordance with Regulations (S) 1.704-2(i)(3).

         "Partner Nonrecourse Debt" shall have the meaning given in Regulations
(S) 1.704-2(b)(4).

         "Partner Nonrecourse Deductions" shall have the meaning given in
Regulations (S) 1.704-2(i)(2).

         "Person" means any natural person, partnership (whether general or
limited), limited liability company, trust, estate, association, or corporation.

         "Profits and Losses" means, for each fiscal year or other period, an
amount equal to the Company's taxable income or loss for such year or period,
determined in accordance with Code (S) 703(a) (for this purpose, all items of
income, gain, loss, or deduction required to be stated separately pursuant to
Code (S) 703(a)(1) shall be included in taxable income or loss), with the
following adjustments:

              (i)   Any income of the Company that is exempt from federal income
tax and not otherwise taken into account in computing Profits or Losses pursuant
to this provision shall be added to such taxable income or loss;

              (ii)  Any expenditures of the Company described in Code (S)
705(a)(2)(B) or treated as Code (S) 705(a)(2)(B) expenditures pursuant to
Regulations (S) 1.704-l(b)(2)(iv)(i), and not otherwise taken into account in
computing Profits or Losses pursuant to this provision, shall be subtracted from
such taxable income or loss;

              (iii) Gain or loss from a disposition of property of the Company
with respect to which gain or loss is recognized for federal income tax purposes
shall be computed by reference to the Book Value of such property, rather than
its adjusted tax basis;

              (iv)  In lieu of the depreciation, amortization, and other cost
recovery deductions taken into account in computing taxable income or loss,
there shall be taken into account the Depreciation on the assets for such fiscal
year or other period; and

              (v)   Any items which are separately allocated pursuant to
Sections 10.1 and/or 10.2 which otherwise would have been taken into account in
calculating Profits and Losses pursuant to the above provisions shall not be
taken into account and, as the case may be, shall be added to or deducted from
such amounts so as to be not part of the calculation of the Profits or Losses;
and

                                      -21-

<PAGE>

              (vi)  Any income of the Company that is recognized as a result of
receiving a Member Recovery Amount shall be excluded from the calculation of the
Profits and Losses, and shall be specially allocated in accordance with Section
6.2.

         If the Company's taxable income or loss for such year, as adjusted in
the manner provided above, is a positive amount, such amount shall be the
Company's Profits for such year; and if negative, such amount shall be the
Company's Losses for such year.

         "Profits" shall have the meaning provided above under the heading
"Profits and Losses."

         "Regulations" means the Regulations promulgated under the Code, and any
successor provisions to such Regulations, as such Regulations may be amended
from time to time.

         "Tax Matters Partner" shall have the meaning given in Section 7.4.

         "Terminating Capital Transaction" means a sale or other disposition of
all or substantially all of the assets of the Company.\

         "Trademark Agreement" means the Trademark License Agreement of even
date herewith between AI and the Company.

         "Transfer" and any grammatical variation thereof shall refer to any
sale, exchange, issuance, redemption, assignment, distribution, encumbrance,
hypothecation, gift, pledge, retirement, resignation, transfer, or other
withdrawal, disposition, or alienation in any way as to any interest as a
Member. Transfer shall specifically, without limitation of the above, include
assignments and distributions resulting from death, incompetency, Bankruptcy,
liquidation, and dissolution.

         The definitions set forth in the Act shall be applicable, to the extent
not inconsistent herewith, to define terms not defined herein and to supplement
definitions contained herein.

                                      * * *

                                      -22-

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Operating
Agreement under seal as of the day and year first above written.

MANAGERS:                                 MEMBERS:

/s/ Robert C. Bishop                      AUTOIMMUNE INC.
--------------------
                                          By: /s/ Robert C. Bishop
                                              --------------------
/s/ Scott A. Gubler                            Name: Robert C. Bishop
-------------------                            Title: Chairman and CEO

/s/ Mark H. Gubler                        DESERET LABORATORIES, INC.
------------------
                                          By: /s/ Scott A. Gubler
                                              -------------------
                                               Name: Scott A. Gubler
                                               Title: President, CEO

                                      -23-

<PAGE>

                                   SCHEDULE I

                             TO OPERATING AGREEMENT
                                 OF COLLORAL LLC

A.       MANAGERS

         Scott A. Gubler
         Mark H. Gubler
         Robert C. Bishop, Ph.D.

B.       TAX MATTERS PARTNER

         Deseret Laboratories, Inc.

C.       MEMBERS

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------
     Name, Address                Capital Contrib. (cash or          Percentage                      Capital
                                                    -------
     and Tax  I.D. No.                 value of property)             Interest     Issue Date        Account
     ----------------                  -----------------              --------     ----------        -------
------------------------------------------------------------------------------------------------------------------
<S>                               <C>                                <C>           <C>               <C>
Name: AutoImmune Inc.             (a)  The License Agreement and
Address: 1199 Madia Street             the Trademark Agreement          51%
Pasadena, CA 91103-1961                pursuant to which AI
SSN: 13-238-9062                       licenses to the Company
                                       certain intellectual
                                       property.

                                  (b)  The machinery and equipment
                                       listed on Schedule II, such
                                       machinery and equipment is
                                       being transferred to the
                                       Company "as is" without any
                                       representations or
                                       warranties whatsoever.
------------------------------------------------------------------------------------------------------------------
Name: Deseret Laboratories, Inc.                $*                      49%
Address: 1414 East 3850 South
St. George, Utah 84790
SSN: 87-047-6826
------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      -24-<PAGE>

                                                                   Exhibit 10.36

                                LICENSE AGREEMENT

                                     between

                                 AUTOIMMUNE INC.

                                       and

                                  COLLORAL LLC

                           dated as of August 19, 2002

<PAGE>

<TABLE>
<S>                                                                                   <C>
ARTICLE 1. DEFINITIONS ..............................................................  1
ARTICLE 2. LICENSE GRANT ............................................................  2
 2.1    Grant of License Rights by AutoImmune to Licensee ...........................  2
 2.2    Sublicenses .................................................................  2
 2.3    Reserved Rights of the U.S. Government and Brigham & Women's Hospital .......  2
 2.4    Marketing and Distribution Rights and Obligations ...........................  3
 2.5    No Other Technology Rights ..................................................  3
ARTICLE 3. INTELLECTUAL PROPERTY ....................................................  3
 3.1    Filing, Prosecution and Maintenance of Patent Rights.........................  3
    3.1.1  Prosecution and Maintenance ..............................................  3
    3.1.2  Abandonment; Failure to Pay ..............................................  3
    3.1.3  Cooperation ..............................................................  3
 3.2    Infringement by Others ......................................................  3
    3.2.1  Prosecution by AutoImmune ................................................  3
    3.2.2  Prosecution by Licensee ..................................................  4
 3.3    Declaratory Actions .........................................................  4
 3.4    Infringement Action Against Licensee ........................................  4
 3.5    Cooperation .................................................................  5
 3.6    Improvements ................................................................  5
ARTICLE 4. CONFIDENTIALITY ..........................................................  5
 4.1    Nondisclosure Obligations ...................................................  5
    4.1.1  General ..................................................................  5
    4.1.2  Limitations ..............................................................  5
 4.2    Terms of this Agreement .....................................................  6
 4.3    Publications ................................................................  6
    4.3.1  Procedure ................................................................  6
    4.3.2  Delay ....................................................................  6
    4.3.3  Resolution ...............................................................  7
 4.4    Prohibition .................................................................  7
 4.5    Injunctive Relief ...........................................................  7
ARTICLE 5. REPRESENTATIONS AND WARRANTIES ...........................................  7
 5.1    Mutual Representations ......................................................  7
    5.1.1  Organization .............................................................  7
    5.1.2  Authorization ............................................................  7
    5.1.3  Binding Agreement ........................................................  7
    5.1.4  No Inconsistent Obligation ...............................................  7
 5.2    Limitations .................................................................  7
    5.2.1  Disclaimer of Warranty ...................................................  7
    5.2.2  Disclaimer of Certain Damages ............................................  8
    5.2.3  Further Limitations ......................................................  8
ARTICLE 6. INDEMNITY ................................................................  8
 6.1    Licensee Indemnity Obligations ..............................................  8
 6.2    AutoImmune Indemnity Obligations ............................................  9
 6.3    Procedure ...................................................................  9
 6.4    Insurance ...................................................................  9
ARTICLE 7. EXPIRATION AND TERMINATION ............................................... 10
</TABLE>

<PAGE>

<TABLE>
<S>                                                                    <C>
 7.1    Termination .................................................  10
    7.1.1  Termination by Either Party ..............................  10
    7.1.2  Termination by AutoImmune ................................  10
 7.2    Survival ....................................................  10
 7.3    Non-Limitation of Rights ....................................  10
ARTICLE 8. MISCELLANEOUS ............................................  10
 8.1    Force Majeure ...............................................  10
 8.2    Assignment ..................................................  10
 8.3    Severability ................................................  10
 8.4    Notices .....................................................  11
 8.5    Applicable Law ..............................................  11
 8.6    Public Announcements ........................................  11
 8.7    Entire Agreement ............................................  12
 8.8    Headings ....................................................  12
 8.9    Independent Contractors .....................................  12
 8.10   Exports .....................................................  12
 8.11   Waiver ......................................................  12
 8.12   Counterparts ................................................  12
 8.13   Interpretation ..............................................  12
 8.14   Identification of Patent Rights; Patent Marking .............  13
</TABLE>

<PAGE>

                                LICENSE AGREEMENT

         THIS LICENSE AGREEMENT dated as of August 19, 2002 (the "Agreement") is
made between AUTOIMMUNE INC., a Delaware corporation ("AutoImmune"), and
COLLORAL LLC, a Delaware limited liability company ("Licensee").

                                    RECITALS

         1. AutoImmune is a biopharmaceutical company pursuing the development
of therapies for the treatment of inflammatory diseases. AutoImmune's
therapeutic approach is based on oral tolerance induction, a method of
controlling a variety of immune-related disorders through the use of the body's
natural immunosuppressive mechanisms.

         2 During the course of its work in the area of inflammatory disease
research, AutoImmune has developed certain proprietary technology related to
methods and formulations for treating diseases.

         3. AutoImmune is interested in licensing this technology for use in the
Field (as hereinafter defined) to a third party which can maximize its potential
by making, having made and selling products embodying such technology on a
worldwide basis.

         4. Licensee is interested in obtaining an exclusive, worldwide license
to AutoImmune's technology in the Field.

         5. AutoImmune is willing to grant such a license upon the terms and
conditions set forth below.

         NOW, THEREFORE, in consideration of the premises and of the covenants
herein contained, the parties hereto mutually agree as follows:

                             ARTICLE 1. DEFINITIONS

         1.1 "Affiliate" shall mean any corporation or other entity which
directly or indirectly controls, is controlled by or is under common control
with a party to this Agreement. A corporation or other entity shall be regarded
as in control of another corporation or entity if it owns or directly or
indirectly controls more than fifty (50%) of the voting stock or other ownership
interest of the other corporation or entity, or if it possesses, directly or
indirectly, the power to direct or cause the direction of the management and
policies of the corporation or other entity or the power to elect or appoint
fifty percent (50%) or more of the members of the governing body of the
corporation or other entity.

         1.2 "Effective Date" shall mean the date first written above.

         1.3 "Field" shall mean the use of Licensed Products as a
non-prescription product for the treatment of arthritic conditions.

         1.4 "Improvements" shall mean all inventions, whether or not
patentable, information, know-how and data of any kind owned or controlled by,
or licensed (with the right

<PAGE>

to sublicense) to, Licensee, at any time during the term of this Agreement for
use in connection with the development, manufacture or use of Licensed Products.

         1.5 "Licensed Products" shall mean any product, or any method of making
or using such a product, which, but for the license granted herein, would be
within a Valid Claim of a pending patent application included in the Patent
Rights or which would infringe a Valid Claim of a pending patents application or
an issued patent included in the Patent Rights.

         1.6 "Patent Rights" shall mean the United States and foreign patent
applications and/or issued patents set forth in Exhibit A hereto; any division,
continuation or continuation-in-part of any such applications; any foreign
patent applications corresponding to any such patent applications; and any U.S.
or foreign patents or the equivalent thereof issuing thereon or any reissue or
extension thereof.

         1.7 "Technical Information" shall mean information, data and knowledge
currently in AutoImmune's possession and as to which AutoImmune has the right to
grant licenses in the Field relating to manufacturing procedures for Licensed
Products in the Field.

         1.8 "Third Party" shall mean any entity other than AutoImmune or
Licensee.

         1.9 "Valid Claim" shall mean either (a) a claim of an issued and
unexpired patent which has not been held permanently revoked, unenforceable or
invalid by a decision of a court or other governmental agency of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal, and
which has not been declared to be invalid or unenforceable through reissue or
disclaimer or otherwise or (b) a claim of a pending patent application which
claim was filed in good faith and has not been abandoned or finally rejected
without the possibility of appeal or refiling of said application.

                            ARTICLE 2. LICENSE GRANT

         2.1 Grant of License Rights by AutoImmune to Licensee. Subject to the
provisions of Section 2.3, AutoImmune hereby grants to Licensee the exclusive
worldwide royalty-free right and license under the Patent Rights and a
non-exclusive worldwide royalty-free right and license under the Technical
Information to use, manufacture, have manufactured, import, offer for sale and
sell the Licensed Products for use in the Field.

         2.2 Sublicenses. Licensee shall have the right to grant sublicenses
under the Patent Rights with the prior written consent of AutoImmune. A copy of
each sublicense granted by Licensee under this Agreement shall be furnished to
AutoImmune promptly after execution thereof. Any such sublicense shall conform
to the terms hereof, and Licensee shall be responsible for the performance by
its sublicensees of all obligations imposed under the terms of this Agreement.

         2.3 Reserved Rights of the U.S. Government and Brigham & Women's
Hospital. Licensee acknowledges that the license granted herein is subject to
any rights of the United States Government under 35 U.S.C.ss.ss.200-212 and a
license retained by the Brigham &

                                        2

<PAGE>

Women's Hospital to use technology developed at the institution for its own
internal research purposes.

         2.4 Marketing and Distribution Rights and Obligations. Licensee shall
have the exclusive worldwide right under the Patent Rights to market and
distribute the Licensed Products. Licensee agrees, at its own expense, to use
diligent efforts to market the Licensed Products to obtain maximum sales of the
Licensed Products.

         2.5 No Other Technology Rights. Except as otherwise expressly provided
in this Agreement, under no circumstances shall a party hereto, as a result of
this Agreement, obtain any ownership interest in or other right to any
technology, know-how, patents, pending patent applications, products or
biological materials of the other party, including items owned, controlled or
developed by the other party, or transferred by the other party to said party,
at any time pursuant to this Agreement.

                        ARTICLE 3. INTELLECTUAL PROPERTY

         3.1   Filing, Prosecution and Maintenance of Patent Rights.

               3.1.1 Prosecution and Maintenance. AutoImmune shall be
         responsible at its expense for the filing, prosecution and maintenance
         of the Patent Rights in its own name, keeping Licensee informed.

               3.1.2 Abandonment; Failure to Pay. AutoImmune agrees that it will
         not abandon the prosecution of any patent applications included within
         the Patent Rights nor shall it fail to make any payment or fail to take
         any other action necessary to maintain a patent under the Patent Rights
         unless it has notified Licensee in sufficient time for Licensee to
         assume such prosecution or make such payment. If AutoImmune elects not
         to continue to seek or maintain patent protection on any patent or
         patent application included in the Patent Rights, subject to any rights
         of Third Parties granted prior to the Effective Date, Licensee shall
         have the right, at its option and expense, but in the name of
         AutoImmune, to prepare, file, prosecute (including oppositions) and
         maintain such patent applications and patents; provided, however, that
         the rights of the parties with respect to any such Patent Rights in all
         other respects shall be as described in this Agreement.

               3.1.3 Cooperation. Each party shall make available to the other
         party (or to the other party's authorized attorneys, agents or
         representatives), its employees, agents or consultants to the extent
         reasonably necessary or appropriate to enable the appropriate party to
         file, prosecute and maintain patent applications and resulting patents
         as set forth in this Section 3.1 for periods of time reasonably
         sufficient for such party to obtain the assistance it needs from such
         personnel. Where appropriate, each party shall sign or cause to have
         signed all documents relating to said patent applications or patents at
         no charge to the other party.

         3.2   Infringement by Others.

               3.2.1 Prosecution by AutoImmune. AutoImmune and Licensee shall
         each promptly notify the other in writing of any alleged or threatened
         infringement of patents

                                        3

<PAGE>

         or patent applications included in the Patent Rights licensed hereunder
         to Licensee of which they become aware, and the parties shall consult
         with one another concerning the action to be taken. AutoImmune shall
         have the right, but not the obligation, to prosecute at its own expense
         any such infringement. After repayment to AutoImmune of all of its
         costs and expenses, any recovery or damages derived from such action
         shall be shared equally by AutoImmune and Licensee.

               3.2.2 Prosecution by Licensee. If, within sixty (60) days after
         AutoImmune first becomes aware of any infringement of the Patent
         Rights, AutoImmune declines to prosecute such infringement or fails to
         cause such infringement to terminate or to bring or diligently
         prosecute a suit or action to compel termination, Licensee shall have
         the right, but not the obligation, subject to any rights of Third
         Parties granted prior to the Effective Date, to bring such suit or
         action to compel termination at the sole expense of Licensee. In such
         event, Licensee shall have the right, if AutoImmune is a legally
         indispensable party, to bring such suit or action in the name of
         AutoImmune. AutoImmune shall have the right to join any such suit or
         action brought by Licensee at AutoImmune's expense. Any recovery or
         damages derived from such action shall first be used to reimburse the
         parties for all legal expenses relating to the suit and thereafter
         shall belong entirely to the Licensee if the infringement involves a
         nutraceutical product, otherwise entirely to AutoImmune No settlement,
         consent, judgment or other voluntary final disposition of the suit may
         be entered into without the consent of AutoImmune, which consent shall
         not unreasonably be withheld.

         3.3 Declaratory Actions. In the event that a declaratory judgment
     action alleging invalidity or non-infringement of any of the Patent Rights
     shall be brought against Licensee, Licensee shall promptly notify
     AutoImmune in writing, and the parties shall consult concerning the action
     to be taken. AutoImmune, at its sole option, shall have the right, within
     thirty (30) days after commencement of such action, to intervene, take over
     and duly prosecute the sole defense of the action at its own expense.
     Licensee shall have no obligation to defend any such action, but Licensee
     shall have the right, at its own expense, subject to any rights of Third
     Parties granted prior to the Effective Date, to join in the defense of any
     such suit or action or to defend any such action if AutoImmune has decided
     not to do so within thirty (30) days after commencement of such action.

         3.4 Infringement Action Against Licensee. In the event that a suit or
     action is brought against Licensee alleging infringement of any third-party
     patent right as a result of the exercise of Licensee's rights under Section
     2.1, Licensee shall have the exclusive right to defend such suit or action
     at its sole expense. AutoImmune will confer with and assist Licensee, at
     AutoImmune's expense, in the conduct or settlement of such defense.
     AutoImmune shall have the right to be represented in such suit or action by
     advisory counsel at its expense. Licensee shall not have the right to
     settle any such suit or action without the prior written consent of
     AutoImmune if as a result of such settlement AutoImmune would be obligated
     to make any payment, assume any obligation, part with any property or
     interest therein, be subject to any injunction or order, grant any license
     or other right under the Patent Rights, or acknowledge the invalidity of
     any of the Patent Rights. Any recovery or damages obtained by Licensee in
     relation to any counterclaim or the like filed by Licensee in such suit
     shall be applied first in satisfaction

                                        4

<PAGE>

of any expenses and legal fees of Licensee relating to the suit. Any recovery or
damages still remaining shall belong entirely to the Licensee.

         3.5 Cooperation. In any infringement suit either party may institute to
enforce or defend the Patent Rights or in which either party defends claims of
infringement of third-party patents pursuant to this Agreement or in any
declaratory judgment action defended by a party, the other party shall, at the
request of the party initiating or defending such suit, cooperate at its expense
in all respects and, to the extent possible, have its employees testify when
requested and make available relevant records, papers, information, samples and
the like.

         3.6 Improvements. Licensee hereby grants to AutoImmune a non-exclusive,
worldwide, royalty-free license, including the right to sublicense, to all
Improvements for any purpose. In the event this Agreement is terminated,
AutoImmune shall retain such license.

                           ARTICLE 4. CONFIDENTIALITY

         4.1 Nondisclosure Obligations.

             4.1.1 General. Except as otherwise provided in this Article 4,
         during the term of this Agreement and for a period of five (5) years
         thereafter, both parties shall maintain in confidence and use only for
         purposes specifically authorized under this Agreement (i) information
         and data received from the other party resulting from or related to the
         development of the Licensed Products and (ii) all information and data
         not described in clause (i) but supplied by the other party under this
         Agreement. For purposes of this Article 4, information and data
         described in clause (i) or (ii) shall be referred to as "Information".

             4.1.2 Limitations. To the extent it is reasonably necessary or
         appropriate to fulfill its obligations or exercise its rights under
         this Agreement, a party may disclose to its Affiliates, actual or
         potential, sublicensees, consultants, outside contractors, and clinical
         investigators, Information it is otherwise obligated under this Section
         4.1 not to disclose on a need-to-know basis on condition that such
         entities or persons agree in writing to keep the Information
         confidential for the same time periods and to the same extent as such
         party is required to keep the Information confidential; and a party or
         its sublicensees may disclose such Information to government or other
         regulatory authorities to the extent that such disclosure is reasonably
         necessary to obtain patents or authorizations to conduct clinical
         trials of, and to commercially market, the Licensed Products. The
         obligation not to disclose Information shall not apply to any part of
         such Information that: (i) is or becomes part of the public domain
         other than by unauthorized acts of the party obligated not to disclose
         such Information or its Affiliates or sublicensees; (ii) can be shown
         by written documents to have been disclosed to the receiving party or
         its Affiliates or sublicensees by a Third Party, provided such
         Information was not obtained by such Third Party directly or indirectly
         from the other party pursuant to a confidentiality agreement; (iii)
         prior to disclosure under this Agreement, was already in the possession
         of the receiving party or its Affiliates or sublicensees, provided such
         Information was not obtained directly or indirectly from the other
         party pursuant to a confidentiality agreement; (iv) can be shown by
         written

                                        5

<PAGE>

         documents to have been independently developed by the receiving party
         or its Affiliates without breach of any of the provisions of this
         Agreement; or (v) is disclosed by the receiving party pursuant to
         interrogatories, requests for information or documents, subpoena, civil
         investigative demand issued by a court or governmental agency or as
         otherwise required by law, provided that the receiving party notifies
         the other party immediately upon receipt thereof and provided further
         that the receiving party furnishes only that portion of the Information
         which it is advised by counsel is legally required and as to which
         confidential treatment is requested.

         4.2 Terms of this Agreement. Except as provided in Section 8.6 hereof,
AutoImmune and Licensee each agree not to disclose any terms or conditions of
this Agreement to any Third Party without the prior consent of the other party,
except as required by applicable law or pursuant to a confidentiality agreement
no less restrictive than this Article 4. If either party determines that it is
required to file with the Securities and Exchange Commission or other
governmental agency this Agreement for any reason, such party shall request
confidential treatment of such portions of this Agreement as it and the other
party shall together determine. Notwithstanding the foregoing, prior to
execution of this Agreement, AutoImmune and Licensee shall agree upon the
substance of information that can be used as a routine reference in the usual
course of business to describe the terms of this transaction, and AutoImmune and
Licensee may disclose such information, as modified by mutual agreement from
time to time, without the other party's consent.

         4.3 Publications.

             4.3.1 Procedure. Each party recognizes the mutual interest in
         obtaining patent protection for inventions which arise under this
         Agreement. In the event that either party, its employees or consultants
         or any other Third Party under contract to such party wishes to make a
         publication (including any oral disclosure made without obligation of
         confidentiality) relating to this Agreement (the "Publishing Party"),
         such party shall transmit to the other party (the "Reviewing Party") a
         copy of the proposed written publication at least thirty (30) days
         prior to submission for publication, or an abstract of such oral
         disclosure at least thirty (30) days prior to submission of the
         abstract or the oral disclosure, whichever is earlier. The Reviewing
         Party shall have the right (a) to propose modifications to the
         publication for patent reasons, (b) to request a delay in publication
         or presentation in order to protect patentable information, or (c) to
         request that the information be maintained as a trade secret and, in
         such case, the Publishing Party shall not make such publication. If no
         request for delay is made by the Reviewing Party pursuant to (b)
         hereinabove, then the proposed publication may be submitted for
         publication.

             4.3.2 Delay. If the Reviewing Party requests a delay as described
         in Section 4.3.1(b), the Publishing Party shall delay submission or
         presentation of the publication for a period of ninety (90) days to
         enable patent applications protecting each party's rights in such
         information to be filed.

                                        6

<PAGE>

             4.3.3 Resolution. Upon either compliance with the provisions of
         Section 4.3.1 or the receipt of written approval of the Reviewing
         Party, the Publishing Party may proceed with the written publication or
         the oral presentation.

         4.4 Prohibition. The use by Licensee, its Affiliates and sublicensees
of the names "Brigham & Women's Hospital" and "Harvard Medical School" or any
other academic or governmental installation wherein any of the Patent Rights or
Technical Information has originated in connection with the licensure, marketing
or sale of Licensed Products is expressly prohibited.

         4.5 Injunctive Relief. The parties hereto understand and agree that
remedies at law may be inadequate to protect against any breach of any
provisions of this Article 4 by either party or their employees, agent, officers
or directors or any other person acting in concert with it or on its behalf.
Accordingly, each party shall be entitled to the granting of injunctive relief
by a court of competent jurisdiction against any action that constitutes any
such breach of this Article 4, without any requirement to post a bond.

                    ARTICLE 5. REPRESENTATIONS AND WARRANTIES

         5.1 Mutual Representations. AutoImmune and Licensee each represent and
warrant to the other as follows:

             5.1.1 Organization. It is a corporation (in the case of AutoImmune)
         or a limited liability company (in the case of Licensee) duly
         organized, validly existing and is in good standing under the laws of
         Delaware and has all requisite power and authority, corporate or
         otherwise, to execute, deliver and perform this Agreement.

             5.1.2 Authorization. The execution, delivery and performance by it
         of this Agreement has been duly authorized by all necessary action and
         does not violate any provision of any law, rule, regulation, order,
         writ, judgment, injunction, decree, determination or award presently in
         effect having applicability to it or any provision of its charter
         documents or any agreement or other instrument or obligation to which
         it is bound or its assets are subject.

             5.1.3 Binding Agreement. This Agreement is a legal, valid and
         binding obligation of it enforceable against it in accordance with its
         terms and conditions.

             5.1.4 No Inconsistent Obligation. Except as provided in Section
         2.3, it is not under any obligation to any person, or entity,
         contractual or otherwise, that is conflicting or inconsistent in any
         respect with the terms of this Agreement or that would impede the
         diligent and complete fulfillment of its obligations.

         5.2 Limitations.

             5.2.1 Disclaimer of Warranty. Except as provided in Section 5.1,
         the rights granted by AutoImmune herein are provided WITHOUT
         REPRESENTATION OR WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
         PARTICULAR PURPOSE OR ANY OTHER WARRANTY OR REPRESENTATION, EXPRESS OR

                                        7

<PAGE>

         IMPLIED. AUTOIMMUNE MAKES NO REPRESENTATION OR WARRANTY THAT EXERCISE
         OF THE RIGHTS GRANTED IN THIS AGREEMENT WILL NOT INFRINGE A PATENT OR
         OTHER PROPRIETARY RIGHT OF ANY THIRD-PARTY. AUTOIMMUNE ASSUMES NO
         RESPONSIBILITY WHATSOEVER WITH RESPECT TO THE PATENT RIGHTS OR
         TECHNICAL INFORMATION, OR THE USE THEREOF, OR THE MERCHANTABILITY,
         FITNESS OR QUALITY OF THE INFORMATION CONTAINED IN THE PATENT RIGHTS OR
         THE TECHNICAL INFORMATION, OR THE PRACTICE OF THE INVENTIONS CONTAINED
         THEREIN OR THE USE THEREOF, OR THE MANUFACTURE, POSSESSION, USE,
         MARKETING, SALE OR OTHER DISPOSITION, BY LICENSEE OR ANYONE ELSE, OF
         LICENSED PRODUCT(S). Without limitation of the generality of this
         Section, nothing contained herein or in the Patents Rights of Technical
         Information shall be construed as extending any representation or
         warranty with respect to any of the foregoing or the results to be
         obtained thereby.

             5.2.2 Disclaimer of Certain Damages. IN NO EVENT WILL AUTOIMMUNE BE
         LIABLE TO LICENSEE OR ANY OTHER PARTY, REGARDLESS OF THE CAUSE OR
         THEORY OF ACTION (WHETHER CONTRACT, TORT INCLUDING WITHOUT LIMITATION
         STRICT LIABILITY AND NEGLIGENCE, OR OTHERWISE) FOR ANY INCIDENTAL,
         SPECIAL, PUNITIVE, CONSEQUENTIAL OR OTHER EXTRAORDINARY DAMAGES
         RESULTING FROM OR ARISING UNDER THIS AGREEMENT INCLUDING WITHOUT
         LIMITATION THE EXERCISE OF THE RIGHTS GRANTED IN THIS AGREEMENT, THE
         USE OF PATENT RIGHTS OR TECHNICAL INFORMATION, OR THE MANUFACTURE, SALE
         OR USE OF LICENSED PRODUCTS.

             5.2.3 Further Limitations. Nothing in this Agreement shall be
         construed as:

                   (a) a warranty or representation by AutoImmune as to the
             validity or scope of any Patent Rights; or

                   (b) a warranty or representation that anything made, used,
             sold or otherwise disposed of under the rights granted in this
             Agreement is or will be free from infringement of a third-party
             patent or other proprietary right; or

                   (c) a warranty or representation that any of the Technical
             Information has not been, or may not hereafter be, developed
             independently by a Third Party; or

                   (d) conferring by implication, estoppel or otherwise any
             license or other right under patents or technology of AutoImmune.

                              ARTICLE 6. INDEMNITY

         6.1 Licensee Indemnity Obligations. Licensee agrees to defend,
indemnify and hold AutoImmune, its Affiliates and their respective directors,
officers, employees and agents harmless against any and all claims, suits,
losses, judgments, liabilities, damages, costs and fees (including but not
limited to reasonable attorneys' fees) and expenses resulting from or arising

                                        8

<PAGE>

out of (a) the breach by Licensee of its representations and warranties in
Article 5 or any other breach of this Agreement; (b) actual or asserted
violations of any applicable law or regulation by Licensee, its Affiliates or
sublicensees by virtue of which the Licensed Products manufactured, distributed
or sold shall be alleged or determined to be adulterated, misbranded, mislabeled
or otherwise not in compliance with such applicable law or regulation; (c)
claims for personal injury, death, property damage, or monetary loss
attributable to the manufacture, distribution, sale or use of the Licensed
Products by Licensee, its Affiliates or sublicensees; or (d) a recall ordered by
a governmental agency, or required by a confirmed failure, of Licensed Products
manufactured, distributed, or sold by Licensee, its Affiliates or sublicensees.

     6.2 AutoImmune Indemnity Obligations. AutoImmune agrees to defend,
indemnify and hold Licensee, its Affiliates and their respective directors,
officers, employees and agents harmless against any and all claims, suits,
losses, judgments, liabilities, damages, costs, fees (including but not limited
to reasonable attorneys' fees) and expenses resulting from or arising out of the
breach by AutoImmune of its representations and warranties in Article 5 or any
other breach of this Agreement.

     6.3 Procedure. A party or any of its Affiliates or their respective
employees or agents (the "Indemnitee") that intends to claim indemnification
under this Article 6 shall promptly notify the other party (the "Indemnitor") of
any loss, claim, damage, liability or action in respect of which the Indemnitee
intends to claim such indemnification, and the Indemnitor shall assume the
defense thereof with counsel mutually satisfactory to the parties; provided,
however, that an Indemnitee shall have the right to retain its own counsel, with
the fees and expenses to be paid by the Indemnitor, if representation of such
Indemnitee by the counsel retained by the Indemnitor would be inappropriate due
to actual or potential differing interests between the Indemnitee and the
Indemnitor. The indemnity agreement in this Article 6 shall not apply to amounts
paid in settlement of any loss, claim, damage, liability or action if such
settlement is effected without the consent of the Indemnitor, which consent
shall not be withheld unreasonably. The failure to deliver notice to the
Indemnitor within a reasonable time after the commencement of any such action
shall not relieve the Indemnitor of any liability to the Indemnitee under this
Article 6. The Indemnitee and its employees and agents shall cooperate fully
with the Indemnitor and its legal representatives in the investigation of any
action, claim or liability covered by this indemnification. In the event that an
Indemnitee claims indemnity from the Indemnitor and the Indemnitor is finally
held liable to indemnify the Indemnitee, the Indemnitor shall additionally be
liable to pay the reasonable legal costs and attorneys' fees incurred by the
Indemnitee in establishing its claim for indemnity. If either counsel for
Licensee or counsel for AutoImmune represents both Licensee and AutoImmune in
any action to be indemnified under this Article 6 or in any action under Article
3, the parties agree that they will not use that representation to disqualify
that counsel in unrelated matters.

     6.4 Insurance. Licensee shall maintain appropriate product liability
insurance with financially responsible insurance carriers naming AutoImmune as
an additional insured with respect to development, manufacture and sales of the
Licensed Products by Licensee in such amount as Licensee customarily maintains
with respect to sales of its other products. Licensee shall maintain such
insurance naming AutoImmune as an additional insured for so long as it continues
to develop, manufacture or sell the Licensed Products, and thereafter for so
long as Licensee maintains insurance for itself covering such manufacture or
sales.

                                       9

<PAGE>

                     ARTICLE 7. EXPIRATION AND TERMINATION

     7.1 Termination.

         7.1.1 Termination by Either Party. Subject to the provisions of Section
     7.1.2, this Agreement may be terminated by either party upon written notice
     to the other party (i) by reason of a material breach if the breaching
     party fails to remedy such breach within ninety (90) days after written
     notice thereof by the non-breaching party or (ii) upon bankruptcy,
     insolvency, dissolution, liquidation or winding up of the other party.

         7.1.2 Termination by AutoImmune. This Agreement may be terminated by
     AutoImmune by written notice to Licensee if Licensee ceases business
     operations.

     7.2 Survival. The provisions of Articles 3, 4, 5 and 6 and Sections 7.3,
8.1 and this Section 7.2 shall survive the expiration or termination of this
Agreement.

     7.3 Non-Limitation of Rights. Termination of this Agreement pursuant to
Section 7.1 shall not be exclusive or prejudicial to any other rights or
remedies of the non-defaulting party on account of the defaulting party's breach
or default under this Agreement.

                            ARTICLE 8. MISCELLANEOUS

     8.1 Force Majeure. Neither party shall be held liable or responsible to the
other party nor be deemed to have defaulted under or be in breach of this
Agreement for failure or delay in fulfilling or performing any term of this
Agreement when such failure or delay is caused by or results from causes beyond
the reasonable control of the affected party, including but not limited to fire,
floods, embargoes, war, acts of war (whether war is declared or not),
insurrections, riots, civil commotions, strikes, lockouts or other labor
disturbances, act of God or acts, omissions or delays in acting by any
governmental authority or the other party; provided, however, that the party so
affected shall use reasonable commercial efforts to avoid or remove such causes
of nonperformance, and shall continue performance hereunder with reasonable
dispatch whenever such causes are removed. Either party shall provide the other
party with prompt written notice of any delay or failure to perform that occurs
by reason of force majeure. The parties shall mutually seek a resolution of the
delay or the failure to perform as noted above.

     8.2 Assignment. This Agreement may not be assigned or otherwise transferred
by Licensee without the prior written consent of AutoImmune. Any purported
assignment in violation of the preceding sentence shall be void.

     8.3 Severability. Each party hereby agrees that it does not intend to
violate any public policy, statutory or common laws, rules, regulations, treaty
or decision of any government agency or executive body thereof of any country or
community or association of countries. Should one or more provisions of this
Agreement be or become invalid, the parties hereto shall substitute, by mutual
consent, valid provisions for such invalid provisions which valid provisions in
their economic effect are sufficiently similar to the invalid provisions that it
can be reasonably assumed that the parties would have entered into this
Agreement with such valid provisions. In case such valid provisions cannot be
agreed upon, the invalidity of one or several provisions of this Agreement shall
not affect the validity of this Agreement as a whole, unless the invalid

                                       10

<PAGE>

provisions are of such essential importance to this Agreement that it is to be
reasonably assumed that the parties would not have entered into this Agreement
without the invalid provisions.

     8.4 Notices. Any consent, notice or report required or permitted to be
given or made under this Agreement by one of the parties hereto to the other
shall be in writing, delivered personally or by facsimile (and promptly
confirmed by telephone, personal delivery or courier) or courier, postage
prepaid (where applicable), addressed to such other party at its address
indicated below, or to such other address as the addressee shall have last
furnished in writing to the addressor and shall be effective upon receipt by the
addressee.

     If to AutoImmune:

         AutoImmune Inc.
         1199 Madia Street
         Pasadena, CA 91103-1961
         Attn: Robert C. Bishop, Ph.D.
         Chairman of the Board, President
          and Chief Executive Officer
         Telephone: 626 792 1235
         Telecopy:  626 792 1236

     with a copy to:

         Nutter, McClennen & Fish, LLP
         One International Place
         Boston, MA 02110-2699
         Attention: Constantine Alexander, Esq.
         Telephone: 617 439-2595
         Telecopy:  617 310-9597

     If to Licensee:

         Scott A. Gubler or Mark H. Gubler
         Deseret Laboratories, Inc.
         1414 East 3850, South
         St. George, Utah 84790
         Telephone: 435-628-7876
         Telecopy:  435-673-1202

     8.5 Applicable Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware, without giving effect to the
choice of laws provisions thereof, provided, however, that the scope, validity
and enforceability of patents shall be determined in accordance with the
applicable laws of the countries in which such patents have been issued.

     8.6 Public Announcements. The parties agree that press releases and other
announcements to be made by either of them in relation to this Agreement shall
be subject to the

                                       11

<PAGE>

written consent of the other party, which consent shall not be unreasonably
withheld or delayed, except to the extent otherwise required by law. The parties
will agree to issue a joint press release immediately following the execution of
this Agreement, the form and content of which shall be reasonably satisfactory
to both parties.

     8.7  Entire Agreement. This Agreement, together with the Exhibit hereto,
contains the entire understanding of the parties with respect to the subject
matter hereof. All express or implied agreements and understandings, either oral
or written, heretofore made are expressly merged in and made a part of this
Agreement. This Agreement may be amended, or any term hereof modified, only by a
written instrument duly executed by both parties hereto.

     8.8  Headings. The captions to the several Articles and Sections hereof are
not a part of this Agreement, but are merely guides or labels to assist in
locating and reading the several Articles and Section hereof.

     8.9  Independent Contractors. It is expressly agreed that AutoImmune and
Licensee shall be independent contractors and that the relationship between the
two parties shall not constitute a partnership, joint venture or agency. Neither
AutoImmune nor Licensee shall have the authority to make any statements,
representations or commitments of any kind, or to take any action, which shall
be binding on the other, without the prior consent of the other party to do so.

     8.10 Exports. The parties acknowledge that the export of technical data,
materials, or products is subject to the exporting party receiving any necessary
export licenses and that the parties cannot be responsible for any delays
attributable to export controls which are beyond the reasonable control of
either party. AutoImmune and Licensee agree not to export or re-export, directly
or indirectly, any information, technical data, the direct product of such data,
samples or equipment received or generated under this Agreement in violation of
any applicable export control laws or governmental regulations. AutoImmune and
Licensee agree to obtain similar covenants from their licensees, sublicensees
and contractors with respect to the subject matter of this Section 8.10.

     8.11 Waiver. The waiver by either party hereto of any right hereunder or
the failure to perform or of a breach by the other party shall not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other party whether of a similar nature or otherwise.

     8.12 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

     8.13 Interpretation. The parties acknowledge and agree that: (i) each party
and its counsel reviewed and negotiated the terms and provisions of this
Agreement and has contributed to its revision; (ii) the rule of construction to
the effect that any ambiguities are resolved against the drafting party shall
not be employed in the interpretation of this Agreement; and (iii) the terms and
provision of this agreement shall be construed fairly as to all parties hereto
and not in favor of or against any party, regardless of which party was
generally responsible for the preparation of this Agreement.

                                       12

<PAGE>

       8.14 Identification of Patent Rights; Patent Marking. Where appropriate,
all packaging and documentation for the Licensed Products shall include a
notation acknowledging AutoImmune's patent rights in the Licensed Products.
Licensee shall mark, and cause its Affiliates and sublicensees to mark, all
Licensed Products made, sold or used under this Agreement, or their containers,
in accordance with the applicable patent marking laws of each country in which
such Licensed Products are to be sold or offered for sale.

                  [Remainder of Page Left Intentionally Blank]

                                       13

<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first set forth above.

AUTOIMMUNE INC.                             COLLORAL LLC

By /s/ Robert C. Bishop                      By /s/ Scott A. Gubler
   --------------------                         -------------------
   Robert C. Bishop, Ph.D.

Title: Chairman of the Board,               Title: Manager Aug 6th 2002
       President and Chief
        Executive Officer

                                       14

<PAGE>

                                   EXHIBIT "A"

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
Title                                Country          Patent           Application          Filing       Grant
                                                      Number           Number               Date         Date
-------------------------------------------------------------------------------------------------------------------
<S>                                  <C>              <C>              <C>                  <C>          <C>
Treatment of Autoimmune              United           5,869,093        08/328,562           10/24/94      2/9/99
Diseases by Oral                     States
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              United           6,019,971        08/463,946             6/5/95      2/1/00
Arthritis by Oral                    States
Administration of
Collagen
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              United           5,733,547        08/461,586             6/2/95     3/31/98
Arthritis by Oral                    States
Administration of Type I
or Type III Collagen
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              Australia           693232          30409/95             9/1/95     11/5/98
Diseases by Oral
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              Canada           2,092,905         2,092,905           10/15/91      1/8/02
Diseases by Oral
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              Norway                               P931372           10/15/91     Pending
Diseases by Oral
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              South Korea         140841       701083/1993           10/15/91     3/16/98
Diseases by Oral
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              EP                                92900084.2           10/15/91     Pending
Diseases by Oral
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Treatment of Autoimmune              Japan              2635444          4-500704           10/15/91     4/25/97
Diseases by Oral
Administration of
Autoantigens
-------------------------------------------------------------------------------------------------------------------
Pharmaceutical                       Israel               99754             99754           10/15/91     11/5/96
Composition Containing
an Autoantigen or a
Fragment or Analogue
Thereof, forthe Treatment
-------------------------------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

<TABLE>
----------------------------------------------------------------------------------------------------------------------
<S>                                  <C>       <C>              <C>                 <C>            <C>
of Autoimmune Arthritis
and Multiple Sclerosis
----------------------------------------------------------------------------------------------------------------------
Method for Preparation of            United    5,840,848        08/778,467           1/3/97        11/24/98
Type II Collagen                     States
----------------------------------------------------------------------------------------------------------------------
Method for Preparation of            EP                         97903850.2           1/3/97         Pending
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method for Preparation of            Canada                      2,238,439           1/3/97         Pending
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method for Preparation of            Australia    705719          18319/97           1/3/97          9/2/99
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method for Preparation of            Japan                        9-515334           1/3/97         Pending
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Title                                Country   Patent           Application         Filing         Grant
                                               Number           Number              Date           Date
----------------------------------------------------------------------------------------------------------------------
Method for Preparation of            Israel                         124834           1/3/97         Pending
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   United    5,399,347        07/951,565          9/25/92         3/21/95
Rheumatoid Arthritis with            States
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   United    5,843,445        08/124,985          9/21/93         12/1/98
Rheumatoid Arthritis with            States
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   United    5,783,188        08/480,180           6/7/95         7/21/98
Rheumatoid Arthritis with            States
Type Collagen Peptide
Fragments Containing
Repeating Sequences
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   United    5,720,955        08/480,137           6/7/95         2/24/98
Rheumatoid Arthritis with            States
Soluble Collagen
----------------------------------------------------------------------------------------------------------------------
Use of an Active                     Israel       107050            107050          9/20/93          4/2/00
Fragment or an Active
Analog of Collagen in the
Preparation of a
Medicament for Treating
Rheumatoid Arthritis
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   Japan                        6-509198          9/24/93         Pending
Rheumatoid Arthritis with
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   Israel                         110899           9/8/94         Pending
Rheumatoid Arthritis with
Type II Collagen
----------------------------------------------------------------------------------------------------------------------
Method of Treating                   United    5,856,446        08/675,886           7/5/96          1/5/99
Rheumatoid Arthritis with            States
Low Dose Type II
Collagen
----------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]